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Abstract 
The Innate immune system is the first line of defense against invading 
microbial pathogens. It is a fast-acting and non-antigen-specific defense system, 
which employs germline encoded surveillance systems capable of responding to 
a broad-spectrum of pathogens. The innate immune system involves a variety of 
immune cells, which express different profiles of surveillance or detection 
receptors. Upon sensing pathogens, these receptors trigger cell signalling to turn 
on transcription of inflammatory cytokines, chemokines, anti-microbial peptides 
and type I Interferons. These effectors have direct effects on the control of 
pathogen load and also activate the adaptive immune system, which is ultimately 
required to clear infections. The type I interferons (IFNs) are the principal 
cytokines strongly induced during infection with viruses and are required for 
direct control of viral replication and modulation of cells of the adaptive immune 
response. The signalling pathways induced in order to activate type I IFNs are 
dependent on the interferon regulatory factors (IRFs). Striving for survival, 
microbes have evolved various strategies to subvert/impair these critical defense 
molecules. 
In this thesis work, I have used Human Metapneumoviruses (HMPVs), a 
relatively newly described family of paramyxoviruses as model viruses to explore 
the role of pattern recognition receptors (PRRs) and the IRF family of 
transcription factors in the innate immune response. These studies revealed that 
the recognition of HMPV viral pathogen-associated molecular patterns (PAMPs) 
xvi
by immune cells is different in different cell types. Retinoic acid-inducible gene-I 
(RIG-I), a cytosolic RNA helicases senses HMPV-A1 virus for triggering type I 
IFN activation by detecting its 5’- triphosphate viral RNA in most human cells, 
including cell lines and primary monocytes. An exception to these findings was 
plasmacytoid dendritic cells (PDCs), where Toll-like receptor (TLR)-7 is the 
primary sensor involved in detecting HMPV viruses.  By comparing the innate 
immune response to two HMPV strains, we found that these two closely related 
strains had very different immune stimulatory capabilities. HMPV-1A strain 
triggered type I IFNs in monocytes, PDCs and cells of epithelial origin. In 
contrast, a related strain, HMPV-B1 failed to trigger IFN responses in most cell 
types.  Our studies suggested that the phosphoprotein (P) of HMPV-B1 could 
prevent the viral RNA from being detected by RIG-I, thus inhibiting the induction 
of type I IFN production in most cell type examined. This finding adds to our 
understanding of the mechanisms by which viruses are sensed by surveillance 
receptors and also unveils new means of viral evasion of host immune 
responses.  
Although IRFs are extensively studied for their role in regulating type I IFN 
activation, especially in TLR and RIG-I like receptor (RLR) signalling pathways 
upon viral infection, a clear understanding of how this family of transcription 
factors contributes to anti-viral immunity was lacking. Studies conducted as part 
of this thesis revealed that in addition to IRF3 and IRF7, which play a central role 
in anti-viral immunity downstream of most PRRs (e.g. TLRs, RLRs, DNA 
xvii
sensors), the related factor IRF5 was also an important component of innate anti-
viral defenses. Using IRF5-deficient mice we studied in detail the role of IRF5 in 
coordinating antiviral defenses by examining its involvement in signalling 
downstream of TLRs. These studies led us to examine the role of IRF5 in the 
regulation of type I IFNs as well as inflammatory cytokines in different cell types. 
While most TLRs that induced IFNβ showed normal responses in IRF5-deficient 
mice, CpG-B-induced IFNβ production in CD11c+CDCs isolated from mouse 
spleen but not those generated in vitro from bone marrow required IRF5. This 
was in contrast to responses with lipopolysaccharide (LPS) or polyriboinosinic 
polyribocytidylic acid (polyIC), ligands for TLR4 and 3, respectively. Moreover, 
we found that in contrast to IRF3 and/or IRF7, IRF5 was important in 
coordinating the expression of inflammatory cytokines such as TNFα 
downstream of some TLRs. In addition to our studies to examine the requirement 
for IRF5 in TLR signaling, we also showed that muramyl peptide (MDP) from 
Mycobaterium tuberculosis (Mtb) could activate type I IFNs via IRF5. This was 
the first evidence linking IRF5 to a non-TLR-driven pathway.  IRF5 activation in 
this case was downstream of a novel nucleotide-binding oligomerization domain 
containing (NOD)-2/receptor-interacting serine-threonine kinase (RIP)-2 signaling 
pathway.  
Collectively, the studies outlined in this thesis have assisted in providing a 
framework to understand the role of TLRs, RLRs and IRFs in the immune 
response to paramyxoviruses and have unveiled new mechanisms of activation 
xviii
of the IRFs as well as new mechanisms by which pathogens subvert or evade 
these important innate defense mechanisms. 
1Chapter I Introduction 
 
1.1 The Innate immunity 
1.1.1 Introduction 
The integrated human immune response comprises two major parts: the 
innate and the adaptive arms. The innate immune system is the first line of host 
defense against microbial infection after the physiological barriers (such as intact 
skin, tears, and mucous membranes) have been breached. Thinking that only 
vertebrates developed adaptive immunity while other organisms only have innate 
immune system to survive from pathogen attack, it is obvious that the innate 
immune response plays a very important role in protecting the host from infection 
or injury. The innate immune system is known as a non-antigen-specific defense 
system, which employs germline-encoded receptors and signaling components 
to enable it to respond to a broad-spectrum of pathogens. The response is fast-
acting, beginning within minutes of pathogen exposure. While the innate immune 
response has no memory or lasting protection, it plays a critical role in activating 
the subsequent adaptive immune response, including the ability to evoke 
memory such that the response reacts quickly upon re-exposure to the same 
pathogen. In contrast to the innate immune system, the adaptive immune system 
is much slower acting and highly antigen specific as it is shaped by the antigen 
through somatic recombination of T and B lymphocytes. Memory T and B cells 
are subsequently developed for immunological memory.  
2In contrast to the adaptive immune system, which mainly employs T and B 
lymphocytes, the innate immune system involves a wide variety of cells of both 
lymphoid and myeloid lineages including monocytes, macrophages, dendritic 
cells (DCs), mast cells, neutrophils, natural killer (NK) cells, and NK T cells. 
Besides the cellular defenses, which also produce cytokines and chemokines to 
enhance the cell-mediated immune response, the innate immune response also 
contains an important humoral component with effector molecules, such as 
complement system proteins and antimicrobial peptides being involved for direct 
action on invading pathogens.  
1.1.2 Cellular players  
Monocytes. Circulating in the blood under steady state, monocytes are 
precursor cells for macrophages and dendritic cells. Microbial infection rapidly 
triggers monocytes to produce inflammatory cytokines and chemokines. There 
are two major subsets of human monocytes (CD14+ and CD16+) (1) and murine 
monocytes (Ly6C+ and CX3CR1+) (2). They express different levels of adhesion 
receptors and respond to distinct trafficking cues, and as a consequence 
differentiate into DCs or macrophages. 
Macrophages. Macrophages are the most active and efficient 
phagocytes, which differentiate from circulating monocytes. F4/80 
(mouse)/EMR1(human) is the most useful specific antigen marker to identify 
macrophage populations (3, 4). Macrophages can be found in many tissues, 
participating in innate response to pathogens as phagocytic cells. They are 
3equipped with a wide range of receptors for phagocytosis including opsonic 
receptors (complement receptors and Fc Receptors) (5, 6) and some pathogen 
recognition receptors (scavenger receptors, c-type lectins etc) (7, 8). When 
macrophages ingest a pathogen, an internal membrane compartment called the 
phagosome is formed, which then fuses with a lysosome, in which, enzymes and 
peroxides digest the pathogen. However some intracellular pathogens, for 
example Listeria monocytogenes (Lm), can escape from the phagosome into the 
cytosol to proliferate (9). Macrophages are also equipped with recognition 
molecules including TLRs (10) and cytosolic RNA helicases (11) that are not 
responsible for phagocytosis, but rather act as sensors which recognize microbial 
products and trigger signaling pathways leading to the production of cytokines 
and chemokines to enhance the immune response. 
Dendritic cells. Dendritic cells (DC) were first identified in 1868 in the 
human epidermis by Paul Langerhans (12). It was not until 1973 when murine 
DCs were identified by Steinman and Cohn in mouse spleen (13). The term 
“dendritic cells” was coined based on the unique morphology of these cells with 
numerous dendrites extending from the main cell body. DCs constitute a 
heterogeneous population of cells that are derived from hematopoietic precursors 
and share common physical, phenotypic and functional characteristics. They 
develop from bone marrow-derived hematopoietic stem cells, which diverge into 
lymphoid and myeloid lineages at an early stage of hematopoietic development. 
Most DC subpopulations are derived from myeloid progenitors, which give rise to 
4committed DC progenitors in the bone marrow. These DC precursors then 
migrate from the bone marrow to the lymphoid organs or non-lymphoid organs 
through the blood to give rise to both conventional DCs (also referred to as 
myeloid DCs, CDC/mDC) and PDCs (14). In addition, PDCs can also be derived 
from lymphoid progenitors and therefore differ from conventional lymphoid and 
myeloid cells (15). 
Different DC populations are characterized by their distinct sets of surface 
markers, see Table 1.1 for the examples of surface markers expressed on 
murine DCs and human blood DCs. The CDC/mDC is a heterogeneous group of 
DC of myeloid lineage that can be separated in three distinct groups according to 
their expression of surface markers CD4 and CD8: the CD8+CDC, the CD8-
CD4+CDC and the CD8-CD4-CDC (double negative, DN). Recently, PDC-specific 
markers have been identified and include blood DC antigen 2 (BDCA-2) for 
human PDCs (16) and mouse PDC antigen 1 (mPDCA-1) for murine PDCs (17).  
Commonly, DCs are divided into PDC and CDC/mDC based on their 
functions. PDCs, which consist of only 0.2-0.8% of human blood cells, were first 
identified as the natural type I IFN-producing cells (IPC) (18), as they  can 
secrete 100-1000 times more type I IFN than other blood cell populations upon 
viral infection (19). PDCs produce type I IFN as early as 4hrs following viral 
infection and produce most of their IFNα within 24hrs (15). The quick and robust 
production of type I IFN by PDCs appears to be a direct consequence of their 
constitutively high expression level of IRF7. As such their production of type I 
5Table 1.1 Surface markers expression on murine DCs and human blood DCs. 
6IFNs does not depend on the positive feedback regulation (discussed below) 
required to amplify IFN production and achieve high levels required for efficient 
control of virus infection (20). PDCs also differ from conventional DCs and 
monocytes in the profile of the TLRs that they express. As detailed later in this 
thesis and of particular relevance for my studies, PDCs express high levels of 
TLR7 and TLR9, two TLRs, which are expressed in the endosomal compartment 
where they recognize single strand viral RNA and CpG DNA, respectively. 
Consequently, PDCs are specialized to respond to microbial nucleic acids, 
particularly those from viruses, which access the endosomal compartment. The 
low acidic pH within endosomes enables viral uncoating, conditions, which can 
expose viral genomes to endosomal TLRs. 
CDC/mDCs differ from PDCs phenotypically and functionally. mDCs 
express different surface markers compared to PDCs. For example, CD11c is 
highly expressed on mDCs and is either not expressed or expressed at very low 
levels on PDC. Distinct subtypes of CDC also have differenct functions. For 
instance, the CD8+CDCs appear to be specialized at cross-presentation of 
exogenous antigen to CD8 T cells (21).  mDCs also express different sets of 
TLRs than PDCs: TLR7 and TLR9 are highly expressed on PDCs, while mDCs 
express TLR1, 2, 3, 4, and 8, which allows them to recognize a broader spectrum 
of pathogens (15). Upon viral infection, CDCs produce type I IFN, interleukin (IL)-
12 and other proinflammatory cytokines, although type I IFN levels are much 
lower than those produced by PDC. Besides TLRs, CDCs also express a much 
7wider selection of PRRs, these include the RNA helicases RIG-I and melanoma 
differentiation-associated gene-5 (MDA5), which recognize cytosolic viral RNA to 
activate the type I IFNβ as well as a wide range of cytosolic sensors for DNA. In 
most cell types the type I IFN, IFNβ is induced first as a result of IRF3 activation. 
Upon IFNβ release, IFNα subtypes are then induced as a result of IFNβ signaling 
through its receptor, the IFNα/βR which signals via a JAK/STAT pathway to turn 
on Interferon stimulated genes. One such ISG, IRF7 is upregulated and upon 
activation by many of the same molecules, which activate IRF3, subsequently 
primes further IFNα and β production. The production of IFNα by CDCs is 
dependent on this IFNβ positive loop since IRF7 is not constitutively expressed in 
these cell types (22). 
DCs can also be classified based on their location and function: (i) 
CD11chiMHC-II+ CDC/mDCs in lymphoid organs (spleen, bone marrow, thymus, 
lymph nodes etc) are mainly resident DCs where they function to present 
antigens to T cells (23). (ii) CD11chiMHC-II+ non-lymphoid-organ (skin, intestine, 
kidney, liver etc.) CDC/mDCs are migratory DCs and have the ability to take up 
antigen from the periphery and migrate to the draining lymph node for antigen 
presentation (24). (iii) PDCs are present in both lymphoid organs and non-
lymphoid organs with CD11cint/-MHC-II-/int surface markers. They are professional 
antigen-presenting and IFNα-producing cells after encountering pathogens (25, 
26). 
8To study DCs in the laboratory, two major approaches are used. The first 
involves the generation of DCs in vitro from precursor cells. In the case of human 
cells, monocytes are differentiated into monocyte-derived DCs, while in the 
mouse, bone marrow cells are the precursor cells utilized. The second approach 
involves the isolation of terminally differentiated DCs from mouse tissues. These 
two techniques are detailed further below. 
1) Monocyte-derived DCs are a mixed cell population generated when 
human monocytes or murine bone marrow cells are cultured with GM-CSF 
resulting in a cell population containing phagocytes such as macrophages, as 
well as DCs (14).  These DCs have the characteristics of in vivo DCs in both 
morphology and function. While cultured for several days in recombinant 
cytokines, one caveat to the use of these DCs is the fact that they are somewhat 
primed or preactivated during this procedure. For example, bone marrow derived 
dendritic cells (BMDCs) can be stimulated to secrete nitric oxide while DCs 
isolated from mouse spleens do not appear to possess this activity. Moreover, 
high numbers of BMDCs can inhibit T cell proliferation while DCs isolated by 
other means often fail to do so (27). More recently, Flt3L has been used to 
culture bone marrow cells to produce PDCs. Flt3L treatment results in a mixed 
population of cells with both myeloid DCs and PDCs.  
2) DCs isolated from lymphoid organs: splenic and thymic DCs each 
contain these subtypes: PDCs, the CD8+CDC, the CD8-CD4+CDC and the CD8-
CD4-CDC. Whether from spleen or thymus, they express different sets of 
9chemokine receptors (CCRs) and TLRs and produce different chemokines (28). 
Recent reports have quantitatively showed differential expression of PRRs 
between DC subtypes (29) and as a consequence these different cells can have 
differential abilities in viral recognition (30).  
Natural killer cells. NK cells are granular lymphocytes with natural 
cytotoxicity as well as cytokine-producing functions. NK cells can kill virally 
infected or transformed cells by direct cell contact. NK cells use two major 
pathways to kill target cells by apoptosis: i) exocytosis of toxic granules (perforin, 
granzymes etc.) and ii) engagement of death receptors on target cells with their 
ligands expressed on NK cell surfaces (e.g. Fas/FasL, TRAIL-R/TRAIL). Besides 
killing, NK cells also secrete cytokines and chemokines, including IFNγ, which 
restricts viral infection as well as stimulates adaptive immunity (31). NK cells play 
an important role in immunity to a wide range of viral infections (32).  Due to the 
powerful ability of NK cells to quickly kill target cells without requiring antigen-
specific recognition, the activation of NK cells is tightly regulated by a balance 
between activating and inhibitory receptors. Inhibitory receptors (mostly MHC 
class I-specific receptors) mediate “self-tolerance” while activating receptors give 
NK cells the signal to eliminate the target cells (33). The function of NK cells is 
also regulated by the cytokine microenvironment surrounding them, including 
type I IFN and IL-12 (32).  
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1.2 Pattern recognition receptors 
As the first line of defense against invading microbes, the innate immune 
system initiates the immediate recognition of invading pathogens. In contrast to 
the adaptive immune system, which develops a broad repertoire of antigen-
specific receptors, the innate immune system responds to a broad spectrum of 
pathogens with only a limited repertoire of germline-encoded receptors. The 
innate immune receptors can recognize three categories of signals: i) The 
exogenous common biological components shared by groups of pathogens, so 
called PAMPs; ii) the endogenous metabolic molecules produced during cell 
damage upon infection, which is called the danger-associated molecular patterns 
(DAMPs), such as alarmins; iii) the inhibitory signals expressed by healthy cells 
but not by infected cells or non-self pathogens, such as major histocompatibility 
complex (MHC) class I molecules, which usually inhibit the innate immune 
response to the cells expressing these signals (34).  
Microbial PAMPs include lipids (e.g. LPS) as well as proteins such as 
flagellin. These ligands can be recognized by different groups of receptors to 
induce appropriate effector responses such as cytokines and chemokines 
immediately upon infection. In addition to classic PAMPs and DAMPs, nucleic 
acids are a particularly potent trigger of innate immune receptors. PAMPs, 
DAMPs and nucleic acids are usually detected by PRRs such as TLRs, RLRs, 
NOD-like receptors (NLRs) and cytosolic DNA sensors (Figure 1.1). 
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Figure 1.1 Pattern recognition receptors. (i) TLRs: TLR1, 2, 4, 5, 6, and 10 appear to 
localize at the cell surface, while TLR3, 7, 8 and 9 are localized inside endosomes. Most 
TLRs employ MyD88 as the adaptor protein for downstream signaling while TLR3 uses 
TRIF.TLR4 uses both MyD88 and TRIF, as well as two additional adapters Mal/TIRAP 
and TRAM. (ii) NLRs: the NLR family members are cytosolic receptors containing a 
central NACHT domain for activation of signaling, a C-terminal LRR domain and N-
terminal CARD or PYD domain for downstream signaling. Some members also have 
Baculoviral inhibition of apoptosis protein repeat domain (BIR, not shown) (iii) cytosolic 
RNA receptors are also called cytosolic RLR family contains RIG-I, MDA5 and LGP2.  
RIG-I and MDA5 recruit the common adaptor protein MAVS through CARD-CARD 
interaction for signaling, while LGP2 only contains a helicase domain.  (iv) cytosolic DNA 
receptors:  DAI was the first identified cytosolic receptor. The Pol III/RIG-I system 
converts polydAdT into a RIG-I ligand.  Recently, two more receptors, the PYHIN 
proteins, Aim2 and IFI16 were also identified as DNA sensors. AIM2 forms an 
inflammasome while IFI16 induces IFN. 
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1.2.1 TLRs 
TLR family members are well conserved from Drosophila to mammals. 
They are type I transmembrane glycoproteins, with extracellular domains 
containing leucine-rich-repeat (LRR) motifs for ligand recognition and intracellular 
Toll/IL-1R (TIR) homology domains responsible for signaling (35). TLRs work as 
dimeric proteins, capable of both homo- or hetero-dimerization, to recognize 
components from bacteria, fungi, parasites, and viruses. To date, 13 murine and 
10 human TLRs have been identified which are expressed at different levels in 
different immune cell types (Table 1.2). Working together, TLRs enable the host 
to detect most types of infection.  
 
1). Endosomal TLRs: TLR3, TLR7/8 and TLR9 
When microbes enter the cells by receptor mediated endocytosis, the 
acidic environment of the phagolysosome leads to their degradation and 
unveiling of their genomes inside endosomes, where the nucleic acid will be 
detected by endosomal TLRs. TLR3 recognizes double stranded (ds)-RNA 
including the replication intermediates of viruses, TLR 7/8 recognize single 
stranded (ss)-RNA, and TLR 9 recognizes unmethylated CpG DNA motifs. TLR3 
is expressed in myeloid cells including conventional/myeloid DCs and monocytes 
as well as on some epithelial cells, but not in PDCs. Moreover the expression 
level of TLR3 can be upregulated by type I IFN. The synthetic dsRNA analog, 
polyIC, can be recognized by TLR3 to induce type I IFN. TLR3 deficient mice
13
Table 1.2 Expression profile of TLRs and RLRs in immune cell types (15, 38). 
 
 
14
showed impaired response to polyIC and resistance to polyIC induced shock 
(36).  While TLR3 was the first PRR implicated in the immune response to RNA 
viruses, TLR3 deficient mice do not display increased susceptibility to most RNA 
viruses. TLR3 does play an important role in influenza A virus (IAV) and West 
Nile virus (WNV) infection. TLR3 expression levels are increased in IAV infected 
pulmonary epithelial cells. TLR3 deficient mice have lower levels of inflammatory 
cytokines, such as Rantes, IL6 and IL12p40/p70 and have longer survival (37).  
In contrast, WNV has been shown to benefit from TLR3 for entry into the brain 
and TLR3 deficient mice are more resistant to lethal WNV infection (39). The 
generation of TLR3 knockouts (KOs) and their analysis in models of viral 
pathogenesis indicated that additional receptors for control of viruses remained 
to be revealed (see below).  
In humans, TLR7 and TLR9 are predominantly expressed in PDCs, while 
TLR8 is expressed in monocytes and myeloid DCs (15, 38). TLR7 can recognize 
single strand viral RNA as well as imidazoquinoline derivatives such as R848 and 
other synthetic ssRNA. TLR7 is one of the most sensitive receptors sensing 
viruses in PDCs. The deficiency of TLR7 in PDCs abrogated the induction of 
IFNα by several RNA viruses, such as influenza virus, Dengue virus and 
vesicular stomatitis virus (VSV) (40-42). It has been reported that human TLR8 
senses GU-rich RNA (43), while murine TLR8 can be activated by a combination 
of poly T oligodeoxynucleotides (ODNs) as well as the TLR agonist 
imidazoquinoline (44). TLR9 recognizes unmethylated CpG DNA motifs that are 
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present in viral and bacterial but not in vertebrate DNA. The induction of IFNα by 
DNA viruses, such as mouse cytomegalovirus (CMV), herpes simplex virus 
(HSV)-1, and -2 as well as murine gammaherpesvirus 68 (MHV-68) are 
dependent on TLR9 in PDCs (45-48). 
 
2). Cell surface TLRs, TLR2, TLR4 and TLR5  
TLR2 forms heterodimers with TLR1 or TLR6 to recognize a variety of 
bacterial components, including lipoproteins, peptidoglycan (PGN) and 
lipoteichoic acid. TLR2 deficient mice are highly susceptible to Staphylococcus 
aureus infection (49) and fail to clear spirochetes after Borrelia burgdorferi 
infection (50). TLR4 associates with MD-2 to recognize the bacterial cell wall 
component LPS. The TLR4-null mice strains, for example C3H/HeJ, show 
reduced response to Gram-negative bacteria and higher susceptibility to 
Salmonella typhimurium infection (51). TLR5 senses flagellin, a component of 
bacterial flagella (52). TLR2 and TLR4 were also shown to recognize viral 
envelope proteins. For example, TLR2 can be activated by Measles virus 
hemagglutinin protein (53), HSV-1 (54) and human CMV (55). TLR4 can be 
activated by Respiratory syncytial virus (RSV) fusion protein (56), and mouse 
mammary tumor virus envelope protein (57).  
 
3) TLR signaling 
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The activation of TLRs is initiated by the engagement of their ligands. The 
extracelluar LRR domain is responsible for the recognition of the PAMPs from 
diverse microbial pathogens. The crystal structures of TLR1-2-Pam3CSK4, TLR3-
dsRNA and TLR4-MD2-LPS complexes that have been determined recently (58-
60) revealing key insights into the activation mechanism for these receptors. The 
ligand binding to the horse-shoe-like LRRs induces the dimerization of TLRs to 
form an “m” shaped dimer, which brings the intracellular TIR domains close 
together to trigger signaling.  
Activated TLRs recruit 2 major adaptor proteins through TIR domain  
interactions: myeloid differentiation primary response gene 88 (MyD88) and TIR-
domain-containing adapter-inducing interferon-β (TRIF). MyD88 is employed by 
all known TLRs except TLR3, which is totally dependent on the adaptor protein 
TRIF. In TLR2 and TLR4 signaling, an additional adaptor named MyD88-adapter-
like (Mal) (also called TIRAP) is also used as a bridging receptor to recruit 
MyD88 to the receptor. TLR4 signals through both MyD88 and TRIF pathways, 
and a fourth adapter protein, TRIF-related adaptor molecule (TRAM), is used to 
recruit TRIF to the receptor. MyD88 and TRIF trigger distinct signaling pathways 
for the production of inflammatory cytokines and type I IFNs. For inflammatory 
cytokine production, MyD88 associates with interleukin-1 receptor-associated 
kinase (IRAK)-4 and IRAK-1, which in turn activate TNF-receptor-associated 
factor (TRAF)-6 to trigger nuclear factor kappa-light-chain-enhancer of activated 
B cells (NFκB) and Mitogen-activated protein (MAP) kinase pathways.  Type I 
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IFN production upon TLR7/9 signaling in PDCs also require MyD88. Binding of 
nucleic acids to TLR7/9 leads to the formation of a protein complex with IRAK4, 
IRAK1, TRAF6, TRAF3 and IRF7, in which IRF7 activation is critical for IFNα 
production. In the case of TLR3/4, type I IFN production relies upon the TRIF 
pathway. TRIF interacts with TRAF6, TRAF3 and RIP1. TRAF3 is responsible for 
the activation of the TANK-binding kinase 1 (TBK1)/IκB kinase (IKK)-ε and 
downstream IRF3 leading to IFNB gene induction (the activation of IRF3 is 
detailed below), while TRAF6 and RIP1 are responsible for the activation of 
NFκB and MAP kinase, leading to the production of inflammatory cytokines (51). 
 
1.2.2 NLRs and inflammasome 
Over the last decade several families of cytosolic pattern recognition 
receptors have been identified. These include the NLR family of proteins, which 
were first identified as important receptors of bacterial components. The NLR 
family members have a central NACHT domain for activation of signaling via 
ATP-dependent oligomerization, a C-terminal LRR domain for ligand recognition 
and N-terminal Caspase recruitment domain (CARD) or pyrin domain (PYD) for 
downstream signaling through protein-protein interactions (61). Among this large 
family, the functions of several members have been more thoroughly studied. 
NOD1 and NOD2 can recognize cytosolic breakdown products of bacterial cell 
walls during bacterial infection, D-glutamyl-meso-diaminopimelic acid (iE-DAP) 
and MDP respectively. Upon ligand binding, NOD1/2 oligomerizes and recruits 
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RIP2 to activate NFκB signaling or CARD9 to trigger MAP kinase signaling. 
Mutations in NOD2 were reported to associate with human inflammatory 
diseases including Crohns disease (62-64). Some other NLRs, such as NACHT, 
LRR and PYD domains-containing protein (NALP)-1, NALP3 and ICE Protease-
Activating Factor (IPAF), upon activation, regulate capase-1 activity through a 
protein complex called the inflammasome.  
The Inflammasome is a protein platform formed upon infection or stress to 
activate the maturation of proinflammatory cytokines, such as IL-1β and IL-18. 
Inflammasome complexes comprise one or more NLR proteins as well as 
caspase-1, and in most cases the adaptor protein apoptosis-associated speck-
like protein containing a CARD (ASC). Of all the NLRs, the NALP3 
inflammasome is the best characterized. It contains NALP3, caspase-1 and ASC, 
which interacts with NALP3 and caspase-1 through PYD-PYD or CARD-CARD 
interactions, respectively. The stimuli described to trigger NALP3 inflammasome 
activity include crystals such as uric acid crystal (65-67), silica (68-70), fungi 
(Candida albicans) (71), bacteria (Lm, Staphylococcus aureus) (72) and viruses 
(Sendai virus (SV), influenza virus, and adenovirus) (73, 74). Although the 
mechanism underlying the activation of NALP3 inflammasome is still not clear, 
recent reports indicate that stimuli induce either cellular stress/danger signals 
including potassium efflux or lysosomal damage, or the generation of reactive 
oxygen species (ROS) to activate NALP3 inflammasome (75). IPAF 
inflammasome consists of IPAF and caspase-1, which interact with each other 
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through CARD-CARD interactions, although in some cases ASC is required for 
maximal activity. IPAF inflammasome can be activated by gram-negative 
bacteria, such as Salmonella typhimurium, Shigella flexneri, Legionella 
pneumophila and Pseudomonas aeruginosa (76-81). The activation of 
inflammasomes results in the activation of caspase-1, which is a cysteine 
protease responsible for the maturation of IL-1β and IL-18 from the inactive pro-
form of these cytokines. IL-1β and IL-18 play important roles in the regulation of 
immune responses, so the integrated regulation of both the production of pro-
form and the activation of caspase-1 through inflammasomes are well controlled.  
 
1.2.3 Cytosolic RNA receptors 
When viruses, especially RNA viruses infect cells, dsRNA and RNA with 
uncapped 5’-triphosphate ends are generated during viral transcription and viral 
replication. These viral products can be sensed by the cytosolic RLR family, 
which contains RIG-I, MDA5 and laboratory of genetics and physiology 2 (LGP2). 
RIG-I and MDA5 contain two N-terminal CARD domains for downstream 
signaling, and a DExD/H RNA helicase domain with ATPase activity. RIG-I also 
contains a C-terminal regulatory domain for inhibiting the function of RIG-I by 
masking the CARD domains in the absence of stimulation (82). Upon viral RNA 
binding, RIG-I will be activated by conformational changes to expose the CARD 
domains, which in turn interact with a CARD domain containing adaptor 
mitochondrial antiviral signaling protein (MAVS) (also called IPS-1, VISA or 
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CARDif) (83-86) through CARD-CARD interaction. Activated MDA5 leads to the 
same signaling pathways as RIG-I by recruiting the same adaptor MAVS. MAVS 
is localized at the mitochondria and in peroxisomes (87), and can recruit TRAF3 
to activate TBK1/IKKε kinases for IRF activation as well as TRAF6 to activate 
IKKα/β for NFκB activation (88). There is also some evidence that MAVS can 
recruit stimulator of IFN gene (STING) for IRF3 activation (89).  
Recent reports indicate that RIG-I and MDA5 selectively recognize 
different RNA motifs. RIG-I recognizes short dsRNA, 5’-triphosphate-ssRNA as 
well as short synthetic dsRNA polyIC (<1kb) while MDA5 recognizes long dsRNA 
and long synthetic dsRNA polyIC (>1kb). RIG-I and MDA5 were thereby 
described to sense different type of viruses. Using RLR deficient mice or cells, 
reports have shown that RIG-I is mostly involved in IAV, VSV, SV, and Newcastle 
Disease Virus (NDV) recognition (90) while MDA5 mainly senses picornaviridae 
(such as Encephalomyocarditis virus (EMCV)) (91) and some murine viruses 
(such as murine norovirus) (92). Several viruses can be detected by both RIG-I 
and MDA5 for different viral RNA products, for example short segments of 
Reoviridae segmented dsRNA genome are substrate of RIG-I, while long 
segments are substrate of MDA5 (91, 93). 
As mentioned above, LGP2 is also a member of the RLR family. LGP2 
has a helicase domain like that found in RIG-I and MDA5, but does not contain a 
CARD domain. LGP2 was reported to negatively regulate RIG-I function in in 
vitro assays (94, 95). Recently, LGP2 deficient mice have shown enhanced type I 
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IFN production in response to polyIC and VSV, while the same deficient mice 
also showed a defect in type I IFN production in response to EMCV (96). 
Additional KO studies from another group, however, suggested that this molecule 
was a positive regulator of the RIG-I, MDA-5 pathways (97). Thus, the function of 
LGP2 in innate immune response to viral infection is still a little unclear. 
 
1.2.4 Cytosolic DNA receptors 
The accumulation of cytosolic DNA during infection or after tissue damage 
has also emerged as an important trigger of innate immunity. Several receptors 
have been identified, which activate distinct functional outcomes with different 
mechanisms. DNA-dependent activator of IRFs (DAI, also called DLM-1 or 
ZBP1) was the first identified candidate cytosolic DNA sensor (98). DAI contains 
at its N-terminus two Z-DNA binding domains that can bind B-DNA. In vitro 
studies using siRNA have shown that DAI is important for type I IFN induction by 
various DNA sources including that from HSV. Although downregulation of DAI 
expression in L929 cells impaired type I IFN response to dsDNA, mouse 
embryonic fibroblasts (MEFs) appeared normal when expression of DAI was 
knocked down (99). Moreover, DAI deficient cells showed normal immune 
responses to poly(dA-dT)·poly(dA-dT) stimulation and DAI-deficient mice had 
normal responses to a DNA vaccine (100). These results indicate that the 
immune response to cytosolic DNA stimulation is cell type dependent, and DAI 
may only play a partial or redundant role in cytosolic DNA sensing. Recently two 
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groups suggested that transfected poly(dA-dT)·poly(dA-dT) could be transcribed 
into RNA ligands for RIG-I by polymerase III in the cytosol, which provides an 
alternative cytosolic DNA recognition mechanism (101, 102). However, the type I 
IFN production in response to poly(dA-dT)·poly(dA-dT) is not RIG-I dependent in 
mouse myeloid dendritic cells (101), which suggested the existence of additional 
DNA sensors, the identity of which remain unknown. Most recently, a new 
receptor for this pathway, IFI16, was identified. IFI16 is a PYHIN (PYD- and HIN 
domain) protein, which can bind to viral DNA and turn on IFNB gene transcription 
(Bowie et. al, Manuscript in press, Nat. Immunology). 
While initial studies on cytosolic DNA receptors mostly focused on the 
induction of type I IFN. Recently it was shown that cytosolic DNA delivery could 
also active the inflammasome and thereby induce IL-1β release. Four 
independent groups identified Absent in melanoma 2 (AIM2) as a cytosolic DNA 
receptor to induce inflammasome activation for IL-1β maturation (103-106). 
AIM2, like IFI16, is a member of HIN-200 family, containing a C-terminal HIN 
domain for DNA binding, and an N-terminal PYD domain to associate with 
adaptor protein ASC to recruit caspase-1. AIM2 can sense cytosolic dsDNA 
poly(dA-dT)·poly(dA-dT) as well as DNA PAMPs from viruses or bacteria. AIM2 
deficient cells lost inflammasome activation in response to Francisella tularensis 
live vaccine strain (LVS), vaccinia virus (VV) and mouse CMV. In addition, 
inflammasome activation by Lm is partially dependent on AIM2 signaling (72, 
107-110). Given the broad-spectrum of DNA pathogens as well as aberrant self 
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DNA that can arise during certain situations (e.g. Systemic Lupus Erythematosus 
(SLE)), it is not surprising that redundant cytosolic DNA sensors exist and lead to 
different signaling pathways.  
 
1.3 Type I IFN production and regulation 
When PRRs detect invading pathogens, they initiate signaling pathways 
leading to the production of multiple cytokines and chemokines for host defense. 
The type I IFNs are the principal cytokines strongly induced during infection by 
viruses and bacteria. They are well known for their antiviral functions by inhibiting 
viral replication either directly or indirectly or by promoting apoptosis of infected 
cells through induction of IFN stimulated genes. Type I IFNs signal through IFN 
receptors in an autocrine or paracrine manner. The enhanced susceptibility of 
type I IFN receptor KO mice to virus infection have shown the critical importance 
of type I IFN for antiviral defenses (111, 112). Besides, type I IFN plays important 
roles in modulating the adaptive immune system. For example, IFNα and β can 
upregulate class I MHC molecules and promote DC maturation, thus facilitate 
antigen presentation (113). Type I IFNs comprise a growing family of IFN 
proteins, among these, IFNα/β are the best studied and will be referred to when 
talking about type I IFN. 
 
1.3.1 The induction of type I IFN  
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The promoter of the IFNB gene contains at least 4 important positive 
regulatory elements called PRDI to IV (114). PRDI and III have overlapping 
binding sites for interferon regulatory factors (IRFs), PRDII is the binding site for 
NFκB and PRDIV for activating transcription factor 2 (ATF2)/c-Jun activated 
downstream of the c-Jun N-terminal kinase (JNK) and p38 MAP kinases. 
Activation of the IFNβ promoter requires activation of all these transcription 
factors and formation of a protein complex called the enhancesome (115) that 
also contains the co-activators such as cAMP response element-binding (CREB)-
binding protein (CBP) or p300. The IFNA gene promoter only has binding sites 
for the IRFs and lacks NFκB binding sites (116). In most cell types, IFNα is 
induced by a positive feedback mechanism involving IRF7, which is itself an 
Interferon Stimulated Gene (ISG) (117, 118) (detailed below). Thus, IRFs are 
essential transcriptional factors required for the induction of type I IFN.  
 
IRFs 
The IRFs are a family of transcriptional regulators with multiple functions, 
such as modulation of innate and adaptive immune responses and immune cell 
development. The IRF family contains 9 members, IRF1 through 9. All of them 
have well conserved N-terminal DNA binding domains (DBDs), which is 
characterized by several 5-tryptophan-repeats. The DBD forms a helix-loop-helix 
motif recognizing GAAA and AANNNGAA sequences. The C-terminal part of the 
IRFs is less conserved. IRF3-9 contain IRF-associated domain (IAD)-1, and IRF1 
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and IRF2 contain IAD2.  These domains mediate protein-protein interactions 
between IRFs and interaction with other proteins such as CBP/p300 (119, 120). 
 1) IRF3 and IRF7 
IRF3 and IRF7 share significant sequence homology to each other, and 
they are the key IRFs regulating type I IFN production during viral infection. TLR 
and RLR activation turn on distinct downstream signaling that result in TBK1 and 
IKKε kinase activation, which in turn phosphorylate IRF3 at its C-terminal 
regulatory region. Phosphorylation of IRF3 alleviates the auto-inhibitory domain 
of IRF3 and releases its transactivation domain, which permits IRF3 dimerization 
and nuclear translocation. IRF7 undergoes a similar activation procedure, and 
forms heterodimers with IRF3 or homodimers to activate type I IFN transcription 
together with coactivator, such as CBP and p300 (see below Figure 1.3). In 
addition to being activated by RLR and TLR, IRF3 and 7 are also important in 
cytosolic DNA sensing. Type I IFN activation by cytosolic DNA ligand requires 
IRF3 and 7. Moreover, the new adaptor protein in DNA signaling pathway, 
STING (also called MITA), can activate IRF3 (89, 121). 
The induction of IFNα and IFNβ in most cell types (except in PDCs, which 
detailed above in “1.1.2 Cellular players – Dendritic cells”) is regulated 
differentially because of the expression level of IRF3 and IRF7. IRF3 is 
constitutively expressed in the cytosol of these cells, acts as a potent activator of 
IFNβ and IFNα4. While IRF7 can activate both IFNA and IFNB genes, its 
expression level is very low but can be induced by type I IFNs. Thus IFNβ and 
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IFNα4 are strongly induced in early response, while the other IFNα subtypes, 
such as α2, α6 etc. are induced in a delayed manner through a positive feedback 
regulation. The initial expression of IFNβ and IFNα4 trigger the type I IFN 
signaling through the interferon-α/β receptor (IFNAR) (detailed below) to induce 
the expression of IRF7, which then acts on type I IFN genes for the production 
(122) (Figure 1.2).  
 
2) IRF5 
IRF5 was discovered based on its homology to IRF3 and IRF7. In contrast 
to IRF3 and IRF7, which are activated by most if not all viruses, the involvement 
of IRF5 in the innate response to viral infection was less widespread as only 
certain kinds of viruses such as VSV, NDV and HSV activated IRF5 (123, 124). 
Previous work from our lab had implicated IRF5 in the regulation of IFNs 
downstream of TLR7 (125). Surprisingly, however, when IRF5-deficient mice 
were generated it was shown that rather than being a major regulator of IFN 
production, IRF5-deficient cells failed to turn on inflammatory cytokines 
downstream of a wide selection of TLRs. Other viruses such as SV that activate 
IRF3 and IRF7 do not appear to activate IRF5, which indicates that IRF5 is 
activated by different signaling pathways from those acting on IRF3/7 (126, 127).  
IRF5 can interact with MyD88 and TRAF6 and is involved downstream of 
TLR-MyD88 pathway for inflammatory cytokine production. In IRF5 deficient DC 
and macrophages, inflammatory cytokines such as IL-6, TNFα, and IL-12 were 
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Figure 1.2 Type I IFN signaling and positive feedback regulation of type I IFN gene 
expression. IRF3 is constitutively expressed in the cytosol, while IRF7 is expressed at 
very low levels. Upon infection, IRF3 is the first factor to be phosphorylated and 
activated leading to IFNβ and IFNα4 induction, which then trigger the type I IFN 
signaling pathway through the interferon-α/β receptor (IFNAR). IFNα/β binding to the 
receptor promotes the IFNAR1/IFNAR2 dimerization, facilitates the cross-
phosphorylation of TYK2 and JAK1 for activation, which in turn phosphorylate STAT1 
and STAT2. After being activated, STAT1 and STAT2 heterodimers recruit IRF9 (p48) to 
form the transcriptional complex called ISGF3, which translocates into the nucleus to 
activate ISGs, including IRF7. Thus in the late phase of infection, the abundant IRF3 and 
IRF7 can form heterodimers or homodimers to turn on type I IFN genes leading to 
amplification of antiviral responses.   
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severely impaired upon TLR-mediated stimulation. Consistently, IRF5 deficient 
mice show resistance to CpG or LPS lethal shock (128). In contrast, the 
involvement of IRF5 in type I IFN production from these initial studies was not 
clearly addressed and therefore remained somewhat controversial.  
In chapter IV of this thesis, I describe my work, which dissects in detail the 
involvement of IRF5 in the innate response to viral infection, particularly clarifying 
its role in the regulation of type I IFN responses.  
 
3) IRF1 and IRF2 
IRF1 and IRF2 were the first identified IRFs that could bind the IFNα and β 
enhancesome regions (129, 130). However in IRF1 deficient MEFs, type I IFN 
was normally induced (131, 132). IRF2 can bind to the same recognition site as 
IRF-1, and antagonize transcription of IRF1-dependent promoters (119). IRF2 
was known as a negative regulator of type I IFN. IRF2 deficient mice developed 
inflammatory skin disease, and some IFN inducible genes, such as oligo-
adenylate synthetase (OAS) and IRF7 are upregulated (133). Moreover, it is 
reported that IRF2 can bind to the same IFN-stimulated regulatory element 
(ISRE) as Interferon-stimulated gene factor 3 (ISGF3) (134). These results imply 
that the function of IRF2 is not to control the expression of IFNα/β, but rather an 
excessive IFNα/β signaling by attenuating ISGF3 mediated IFN inducible gene 
expression (133).  
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4) IRF9 
IRF9 is a central component of type I IFN signaling. IRF9 forms a complex 
with STAT1 and STAT2, named ISGF3, which is critical for induction of ISGs. In 
IRF9 deficient mice, type I IFN signaling pathways are impaired (135).  
 
5) IRF4,6,8 
IRF4 and 8 share high homology, and are primarily expressed in immune 
cells, such as macrophages and DCs. IRF4 mRNA is induced by various TLR 
ligands, and IRF4 shares the same binding site as IRF5 on MyD88. TLR induced 
IRF4 can compete with IRF5, for MyD88 binding, thus inhibiting IRF5 activity 
(127). Consistent with these observations the level of proinflammatory cytokines 
induced by TLR ligands in IRF4 deficient peritoneal macrophages is elevated, 
which is the opposite of what is seen in IRF5 deficient mice. IRF4 deficient mice 
are more sensitive to CpG-B induced shock. All these data present IRF4 as a 
negative regulator of TLR-dependent IRF5 responses (136).  
IRF8 also plays a role in TLR9 signaling in DCs. In IRF8 deficient DCs, 
CpG induction of proinflammatory cytokines such as TNFα and IL-6 are totally 
abrogated and NFκB was not activated, while the response to LPS remains intact 
(137). IRF8 is also involved in the induction as well as the feedback phase of 
type I IFN induction by virus and TLR in DCs (138). Little is known about the 
function of IRF6 in response to viral infection, while it has been reported that 
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polyIC treatment changes the cytosolic IRF6 phosphorylation pattern and can 
induce a small portion of IRF6 to translocate into nucleus (139). 
 
1.3.2 Type I IFN signaling and ISGs 
The classic signaling pathway for IFNα and IFNβ to induce cellular 
responses employs Janus kinase (JAK) and signal transducer and activator of 
transcription (STAT) factors. In steady state condition, the IFNAR1 is associated 
with tyrosine kinase 2 (TYK2), and IFNAR2 is associated with JAK1. 
IFNα/β binding to the receptor promotes the IFNAR1/IFNAR2 dimerization on the 
cell membrane to initiate a tyrosine phosphorylation cascade. IFNAR1/IFNAR2 
dimerization facilitates the cross-phosphorylation of TYK2 and JAK1 for 
activation, which in turn phosphorylate STAT1 and STAT2. After being activated, 
STAT1 and STAT2 heterodimers recruit IRF9 (p48) to form the transcriptional 
complex called ISGF3, which translocates into the nucleus and binds to the 
ISREs of many type I IFN stimulated genes to regulate their expression (140, 
141) (Figure 1.2). Besides this classic STAT1/STAT2/IRF9 complex pathway, 
type I IFNs also activate other types of STAT complexes, such as STAT3 
homodimers, STAT5 homodimers as well as STAT1-STAT3 heterodimers, all of 
which translocate into nucleus and bind different promoter elements in response 
to type I IFN (142).   
ISGs 
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ISGs contain ISRE elements in their promoters and are inducible by type I 
IFN signaling. They are the effectors of type I IFN for the antiviral, 
antiproliferative and immunomodulatory functions. Over 400 ISGs have been 
identified by microarray analysis including the well known dsRNA-dependent 
protein kinase (PKR), Mx1, ISG15, OAS and RNAseL for their antiviral activities. 
Despite the robust induction of hundreds of ISGs, the biological function of most 
of these genes is poorly understood (143). I will detail below the function of some 
ISGs involved in the type I IFN antiviral activity. 
1) PKR 
PKR is a serine-threonine kinase with a kinase domain at the C-terminus, 
and two dsRNA binding motifs at the N-terminus, which are well conserved 
among the dsRNA-binding proteins. There is no specificity described of dsRNA 
sequence for PKR binding. dsRNA that bind to the RNA binding motif are 
intermediates of replication generated in infected cells by various viruses. For 
example, RNA viruses, such as influenza virus, produce dsRNA intermediates 
when synthesizing new genomic RNA copies. In contrast DNA viruses as VV, 
adenovirus or HSV, transcribe partially complementary mRNA to form dsRNA 
due to the bidirectional open reading frames in their DNA genomes. When 
binding to viral dsRNA, PKR is activated by autophosphorylation and then 
phosphorylates the eukaryotic initiation factor 2a (eIF2a), which in turn inhibits 
viral gene translation (140, 144). Besides, in response to a specific group of RNA 
viruses including EMCV, Theiler's murine encephalomyelitis virus and Semliki 
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Forest virus, PKR is required for IFNα/β production by maintaining the integrity of 
newly synthesized IFNα/β mRNA to promote their translation (145).  
 
2) OAS and RNase L 
OAS protein is located in the cytosol and can be activated by specific 
dsRNA motifs, which usually originated from viral RNA. Activated OAS can 
convert ATP into 2’-5’ linked AMP-oligomers (2-5A), which in turn binds to 
RNAse L monomers and promote the formation of active RNAse L homodimers. 
The N-terminus of RNAse L involves the 2-5A binding and C-terminus contains 
the enzymatic domain involved in viral ssRNA cleavage, thereby inhibiting viral 
protein synthesis. Active RNAse L also cleaves some cellular self mRNA. 
Cleaved cellular RNA can then act as RIG-I ligands and amplify type I IFN 
induction (146). The OAS-RNAse L system is important in response to SV, 
EMCV, WNV and Coxackie virus B4 since cells deficient in RNAse L are more 
permissive to these viruses (140, 144, 147).   
 
3) Mx proteins 
Mx proteins are GTPases, which are strictly controlled by type I IFNs. Mx 
proteins are expressed abundantly in the cytosol and can interfere with viral 
replication by binding to viral nucleocapsid proteins in the cytoplasm and 
inhibiting their trafficking into the nucleus. Mx proteins play a critical role against 
influenza virus, VSV and Measles virus (140, 144, 147). 
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4) Other ISGs 
ISG15 is an IFN inducible gene that conjugates to its target proteins in a 
reversible reaction called ISGylation.  ISG15 has more than 150 target proteins 
identified, such as RIG-I, JAK1, STAT1, MxA, PKR, RNaseL, which are important 
in the innate immune response. Although the function of ISGylation is not yet 
clear, ISG15 has been reported to prevent the degradation of IRF3 thus 
enhancing type I IFN production. Besides its intracellular function, the large 
amount of secreted ISG15 in response to type I IFN may also act as a cytokine 
like molecule to further modulate immune response, while the mechanism is not 
yet clear (148). ISG15 deficient mice are more sensitive to HSV-1, Sindbis virus, 
and influenza virus infection (144, 149). ISG20 is an IFN inducible 3’-5’ 
exonuclease that can cleave viral ssRNA to inhibit viral protein production. It was 
shown that ISG20 had antiviral activity against VSV infection (150). 
 
1.4 Innate immune response to viral infection 
Host cells recognize viral pathogens through PRRs, which in turn activate 
intracellular signaling cascades, leading to the production of type I IFN and other 
cytokines and chemokines. Inflammatory cytokines and chemokines recruit and 
activate effector cells and are often the leading contributor to the morbidity and 
mortality associated with viral pathogenesis. Type I IFN is the major antiviral 
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cytokine, which acts to restrict viral replication and activate other immune cells 
important in viral clearance.  
 
1.4.1 Viral recognition and type I IFN activation 
Viral proteins, viral genomes, or nucleic acids produced during viral 
reproduction are all sensed by PRRs. Three major types of PRRs are currently 
recognized as the cellular sensors involved in the induction of type I IFN by 
viruses: TLRs, RNA helicases and cytosolic DNA sensors. As detailed above in 
“1.2 Pattern recognition receptors”, 
 Of particular relevance to this thesis are the mechanisms underlying the 
sensing of RNA. Endosomal TLRs and cytosolic RLRs can recognize the viral 
RNA to induce type I IFN production. TLR3 recognizes dsRNA, including the viral 
replication intermediates. TLR7/8 recognize single ssRNA, and TLR9 recognizes 
unmethylated CpG DNA motifs. RIG-I senses cytosolic 5’-triphosphate-ssRNA as 
well as short dsRNA, while MDA5 senses long dsRNA.  Cell surface TLRs, TLR2 
and TLR4, can recognize viral proteins to induce proinflammatory cytokine 
production. 
 The detection of viral pathogens for type I IFN production involves 
differential PRRs and signaling components in different cell types. PDCs are 
known to produce large amount of type I IFN and express very high level of TLR7 
and TLR9 and very low level of TLR3, RIG-I and MDA5 (15, 38). Thus PDC are 
mainly dependent on TLR7/9 for their recognition of viral nucleic acids. For 
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example, PDCs induced IFNα in response to NDV is normal in cells lacking RIG-
I, but severely decreased in the absence of MyD88 or TLR7 (151).  In PDCs, 
binding of nucleic acids to TLR7 and TLR9 activates signaling leading to the 
recruitment of the adaptor protein MyD88, which forms a complex with IRAK1 
(152), IRAK4 (153), TRAF6 (154) and TRAF3 (155). The complex activates IRF7 
through IKKα (156) for IFNα production, as well as NFκB and MAP Kinase 
pathways for inflammatory cytokine production.  
In contrast, RLRs play critical roles in the production of type I IFN in a 
variety of other cell types, including conventional DCs. TLR3 has been suggested 
to recognize dsRNA from engulfed apoptotic bodies of viral infected cells (157). 
When TLR3 gets activated, it recruits TRIF, which in turn forms a complex with 
RIP1, TRAF6 and TRAF3 (155, 158-160). RIG-I and MDA5 share the same 
adaptor protein MAVS, which forms a complex with TRAF6 (85) and TRAF3 
(161). Both of these complexes activate IRF3 and IRF7 through TBK1/IKKε (162, 
163) (Figure 1.3). 
Viruses use the endocytic pathway to facilitate their entry into cells as well 
as their exit from cells (164). It is in this compartment where they encounter 
TLRs. PDCs take up viruses as well as inactive viral particles into the endosomal 
compartment, where they get degraded exposing the viral nucleic acid to TLR7 
or TLR9 (165). This process does not require viral replication in the cytosol. In 
the case of viruses that replicate in the cytosol, it is less clear how the viral 
genomes are detected via TLRs. One model is that autophagy is activated in
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Figure 1.3 IFNB Gene Transcription after Viral Infection. Viral nucleic acids are 
mainly recognized by endosomal TLR 3 (dsRNA), TLR9 (CpG DNA) and TLR7/8 
(ssRNA), and cytosolic RLRs, RIG-I (5’PPP-RNA) and MDA5 (dsRNA). In PDCs, 
activated TLR7/8 and TLR9 recruit the adaptor protein MyD88, which forms a complex 
with IRAK1, IRAK4, TRAF6, and TRAF3. This complex activates IRF7 through IKKα for 
IFNα production, as well as NFκB and MAP Kinase pathways for inflammatory cytokine 
production. Activated TLR3 recruits TRIF, which in turn forms a complex with RIP1, 
TRAF6 and TRAF3 to activate NFκB signaling or TBK1 to activate IRF3 and turn on IFN 
genes. RIG-I and MDA5 share the same adaptor protein MAVS, which forms a complex 
with TRAF6 and TRAF3 for type I IFN and inflammatory cytokine production, 
respectively. TRAF3 forms a complex with TBK1/IKKε to phosphorylate IRF3 and IRF7 . 
Phosphorylation of IRF3 alleviates the auto-inhibitory domain and releases the 
transactivation domain, which permits IRF3 dimerization and nuclear translocation. IRF7 
undergoes a similar activation procedure, and forms heterodimers with IRF3 or 
homodimers. Dimerized IRFs activate type I IFN transcription together with coactivator, 
such as CBP.  
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PDC, which delivers RNA products from viruses in the cytosol to endosomal 
TLRs (166). Therefore, endosomal TLRs are not restricted to sensing ligands 
processed through endocytic pathways. Autophagy is a mechanism involved in 
normal turnover of cellular contents, but is also activated upon infection to target 
cytosolic pathogens for destruction in the endosome. Genetic studies using mice 
lacking components of the autophagy machinery (autophagy-related proteins 
(Atgs)) have revealed a role for autophagy in the sensing of cytosolic viruses 
(167). In Atg5 deficient PDCs, the production of both type I IFN and the 
inflammatory cytokine IL-12 p40 induced by VSV and Sendai virus, which 
replicates in the cytosol was severely impaired. The type I IFN production in PDC 
response to these viruses required live viral infection in the cytoplasm and 
endosomal TLR7 (166), which suggested that autophagy is the bridge necessary 
for the TLR7-dependent production of type I IFNs and cytokines in PDCs after 
certain viral infections.  
 
1.4.2 Regulation of type I IFN by viral evasion 
Viruses are rapidly evolving parasites. They require the host cell protein 
synthesis for their survival and reproduction. When host receptors detect viral 
infection, potent cytokines especially type I IFN will be quickly produced to 
directly kill the invaders and induce antigen-specific responses. Viruses have 
evolved all kinds of strategies to block their recognition by the immune system 
and fight against the production of antiviral effectors, so that they can proliferate 
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and spread in the host. These strategies target different stages of the PRR 
signaling, including: 1) interfering with the induction of type I IFN—targeting the 
receptors, the adaptors, the kinases, the transcription factors; 2) interfering with 
IFN-induced signaling and 3) inhibiting interferon effector proteins. Besides the 
evasion of host detection, viruses have also been reported to subvert the host 
signaling for their own benefit. Some examples are shown below. 
 1) Targeting the induction of type I IFN 
Influenza viruses target the type I IFN production pathway at several 
steps. Its NS1 protein can sequester dsRNA produced during viral replication 
thereby preventing the RNA from being detected by the cytosolic receptor RIG-I. 
The NS1 protein also interacts with host Trim25, an E3 ubiquitin ligase essential 
for RIG-I activation. NS1 blocks Trim25 to inhibit RIG-I ubiquitination and binds to 
the adaptor MAVS to block the signaling pathway (168). Ebola virus (EBOV) 
expresses VP35 protein which binds IKKε and TBK1 as a pseudosubstrate to 
block IRF3/7 activation (169). HSV-8 developed a very unique strategy by 
expressing viral homologs of cellular IRFs, called vIRFs, to interfere with both the 
IFN induction and IFN-induced signaling pathway (170).  
2) Targeting type I IFN signaling and effector ISGs 
Vaccinia virus expresses a soluble IFNα/β receptor, B19, which can 
sequester IFNα/β produced by the infected cells, thus blocking IFN downstream 
signaling (171). Ebola virus and Marburg virus, which both belong to the 
Filoviridae family, express VP24 to inhibit the IFNα/β signaling pathway by 
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preventing STAT1 and STAT2 phosphorylation and STAT1 nuclear accumulation 
(169). CMV has evolved mechanisms to directly limit ISG function: hCMV 
proteins pIRS1 and pTRS1, and mCMV proteins pm142 and pm143 can 
counteract PKR pathway directly and inhibiting OAS/RNase L pathway activation 
(172).  
 
1.4.3 Paramyxoviruses 
The paramyxoviridae family includes some of the most prevalent disease-
causing human pathogens as well as viruses infecting other animals (measles 
virus, RSV, parainfluenza virus, metapneumovirus, NDV, SV, Hendra virus, 
Nipah virus, etc.). The family is classified into two subfamilies: 1) the 
paramyxovirinae, which contains five genera, Respirovirus, Rubulavirus, 
Avulavirus, Morbillivirus, and Henipavirus; 2) the Pneumovirinae, which contains 
two genera, Pneumovirus and Metapneumovirus.  Viruses of paramyxoviridae 
are enveloped, containing non-segmented, single stranded negative sense RNA 
genomes. Paramyxoviruses replicate in the cytoplasm of infected cells. The viral 
genome is between 15-19 kb in length and functions as template for two 
purposes: 1) for transcription of mRNA to produce new viral proteins; 2) for 
synthesis of anti-genome positive strand RNA to produce new viral genomes. 
The newly produced genomes and proteins are then packaged with the lipid 
envelopes derived from the plasma membrane of host cells. Paramyxovirus 
genome contains 6-10 genes in conserved order, flanked by transcriptional 
40
control sequences. They encode genome-associated proteins (nucleocapsid 
protein N, phosphoprotein P, and large polymerase L), envelope localizing 
proteins (fusion protein F, attachment protein HN, or H or G, some viruses also 
have a small hydrophobic protein SH), and matrix protein (M). Some viruses also 
encode non-structural proteins (NS).  The P gene also extends the coding 
capacity of some viruses by encoding alternative protein products through “RNA 
editing”, such as V/W/I/D (173).  
N, P, L proteins 
The N protein is an RNA binding protein. It coats both the negative viral 
genome and the positive anti-genome. N protein is a major structural protein. The 
encapsidation of the RNA not only prevents the RNA from host nuclease 
digestion, but also turns the RNA into the biologically active form essential for 
transcription and replication. It also helps for the virion assembly. L protein 
usually associates with N and P protein to form a complex called RNA 
polymerase (RNAP) and L is the catalytic subunit of the RNA dependent RNAP. 
It is believed that L protein is responsible for catalyzing all the synthesis of RNA 
products, including transcription of mRNA and replication of genomic RNA. The P 
protein is a part of the RNAP, essential for viral RNA synthesis. Besides 
encoding the P protein, the P gene from the Paramyxovirinae subfamily has 
overlapping open reading frames that give multiple distinct protein products, such 
as “V”, “C’’, “W”, “D”, or “I” proteins by the process called “RNA editing”. These 
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alternative P gene products are not essential for viral replication but the deletion 
of these products results in severe attenuation. 
F, HN (H or G), SH, and NS proteins 
F protein mediates viral entry by fusion between the viral envelope and the 
host plasma membrane. F protein is synthesized as an inactive form F0, which 
needs to be cleaved by host protease into the active F1 form. The F protein of 
paramyxovirus promotes membrane fusion at neutral pH, with the exception that 
the membrane fusion of certain HMPV strains is induced at low pH (174, 175). 
The F proteins expressed at the host plasma membrane during viral reproduction 
also can mediate the fusion with neighboring cells for virus spread.  
HN (H or G) protein is the cell attachment protein. It binds to the cellular 
receptor to facilitate virus binding to target cells and trigger F-protein mediated 
fusion.  Depending on the activity of the attachment protein, hemagglutinin (H) – 
binding sialic acid, and neuraminidase (N) – cleaving sialic acid, the 
Respirovirus, Rubulavirus and Avulavirus attachment proteins are denoted HN, 
Morbillivirus attachment protein is denoted H, Henipavirus, Pneumovirus and 
Metapneumovirus attachment proteins are denoted G, without H or N activities.  
Some of the viruses, such as PIV5, mumps virus and viruses from 
Pneumovirinae have SH protein. It is a type II integral membrane protein, but the 
function is not yet clear. Pneumovirinae family members also encode NS1 and 
NS2 proteins. While the function of NS proteins in viral growth remains unclear, 
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the NS1 an NS2 proteins from RSV can interfere with host type I IFN production 
(176).  
      
1.4.4 Innate immune response to paramyxoviruses 
Paramyxoviruses, especially SV and NDV, are potent type I IFN inducers. 
Their nucleic acids, or the RNA products produced during viral reproduction can 
be detected by PRRs, including the cytosolic RLRs, RIG-I and MDA5 (94, 151, 
177-181), and in PDCs are sensed by endosomal TLRs, TLR7, TLR8 (177). It 
was also reported that the viral F protein from RSV could activate TLR4 for type I 
IFN production (56, 182).  
Sendai virus (SV) and Newcastle disease virus (NDV) 
SV and NDV both belong to the Paramyxovirinae subfamily. They are 
used in the laboratory as experimental tools to dissect the mechanisms 
underlying the production of type I IFNs. Following the discovery of RIG-I it was 
shown that, both SV and NDV failed to induce type I IFN production in RIG-I-
deficient cells. Similar results were observed in RIG-I deficient bone marrow 
derived CD11c+CDCs. This was in contrast to the response in MyD88/TRIF 
double deficient cells, which suggested the importance of RIG-I in sensing these 
viruses. In contrast to these observations in MEFs and BMDMs, bone marrow 
derived Flt3L-DCs (PDC) showed that the IFN response to these viruses was 
dependent on TLR7. Like SV, NDV induced type I IFN was RIG-I dependent in 
splenic CD11c+CDCs, and was MyD88 dependent in splenic PDCs (151). This 
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differential recognition was also revealed using MAVS deficient cells. MAVS is 
required for the type I IFN and IL-6 activation by SV in MEFs, macrophages, and 
CDCs, but not in PDCs (183). 
 
Respiratory syncytial virus (RSV) and Human metapneumovirus (HMPV) 
RSV and HMPV both belong to Pneumovirinae subfamily. Similar to the 
response to SV and NDV, the type I IFN activation by RSV was also found to be 
RIG-I/MAVS dependent in murine MEFs, macrophages, and CDCs. After in vivo 
infection, IFNα/β and IL6 levels in bronchial lavage fluid were found to be totally 
dependent on MAVS. In contrast, TNFa, MCP-1 and IL-1b were found to be 
dependent on both MAVS and MyD88. In purified bone marrow derived Flt3L-
PDCs, RSV failed to activate type I IFN (184), consistent with the observation 
that the RSV A2 strain can block type I IFN production by human PDCs, probably 
through inhibiting MyD88 signaling pathway (185). There was also a report 
showing that RSV NS1 and NS2 proteins could inhibit type I IFN production in 
A549 cells and human monocyte-derived macrophages (176). 
HMPV is a relatively recently identified member of the paramyxovirus 
family (Figure 1.4). Phylogenetic analysis has revealed two major genetic 
clusters for HMPV, designated as group A and B, which have been further 
subdivided into four main subtypes A1, A2, B1 and B2 (186, 187). At the outset 
of my studies, there was no information available regarding the mechanisms by 
which the immune systems detect HMPV viruses. Although, a recent study has
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Figure 1.4 Schematic diagram of a HMPV. HMPV belongs to the paramyxovirus 
family. It contains a negative-sense single-stranded RNA genome, which forms a 
complex with the L, N and P protein. The virus is enveloped with G, SH and F proteins 
embedded in the Lipid bilayer, and M protein aligning inside. 
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implicated the RIG-I pathway in sensing the HMPV strain CAN97-83 (A2 strain) 
(188).  In Chapters II and III, we investigated the innate immune response to 
HMPV in detail by dissecting the role of TLR and RLR signaling pathways.  
 
1.5 Thesis objective 
This thesis study focuses on understanding the molecular mechanisms 
involved in sensing RNA viruses and the means by which viruses in general turn 
on protective immune responses.  
The objective of this thesis includes: 
1) An investigation of the innate immune sensing of HMPV viruses, by 
examining the receptors and the signaling pathways involved in type I IFN 
induction by this virus. Using different human cell lines as well as primary human 
and murine monocytes and PDCs, we demonstrated that type I IFN production 
during infection with HMPV viruses involves differential sensing mechanisms, 
which work in a cell-type specific manner.  
2) The second objective in this study was to explore the mechanisms 
underlying the differential induction of type I IFN by two closely related HMPV 
stains. These mechanistic studies in particular led us to explore the role of the 
phosphoprotein from HMPVB1 virus and identify this molecule as an immune 
evasion gene interfering with type I IFN induction.  
3) The third objective for my studies was to explore downstream signalling 
pathways in IFN gene regulation. In particular, these efforts focused on defining 
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the function of IRF5 in anti-viral innate immune responses. A careful examination 
of IRF5 deficient cell responses to TLR ligands revealed the involvement of IRF5 
not only in the induction of type I IFNs in response to some TLR ligands in 
specific cell types, but also unveiled the importance of IRF5 in the regulation of 
inflammatory cytokines. Furthermore, we also uncovered a novel role for IRF5 in 
the NOD2-RIP2 pathway in response to Mtb infection.  
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Chapter II innate immune sensing of HMPV 
Abstract 
HMPV are recently identified Paramyxoviridae that contribute to 
respiratory tract infections in children. No effective treatments or vaccines are 
available. Successful defense against virus infection relies on early detection by 
germline encoded pattern recognition receptors and activation of cytokine and 
type I interferon genes. In this study, we investigated the ability of two prototype 
strains of HMPV (A1 [NL\1\00] and B1 [NL\1\99]) to induce type I IFN in different 
cell types. Recently, RIG-I has been shown to sense HMPV. Sensing of 
HMPVA1 virus occurs via RIG-I in most cell types tested including human cell 
lines and purified human monocytes. We have also identified 5’- triphosphate 
RNA as the HMPV viral ligand triggering the RIG-I/IFN-I response. In these cell 
types, HMPVB1 failed to elicit type I IFN production. In contrast, PDC displayed a 
unique ability to sense both the A1 and B1 strains and in this case sensing was 
via TLR-7 rather than RIG-I. Collectively, these data reveal differential 
mechanisms of sensing for two closely related viruses, which operate in cell-type 
specific manners. 
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Introduction 
HMPV is a newly described virus responsible for lower respiratory tract 
infections in children (189). The virus was first isolated in the Netherlands in 
2001. Compared to its closest human relative, RSV, HMPV has a worldwide 
prevalence and causes a broad spectrum of illnesses that range from 
asymptomatic infection to severe bronchiolitis. Serological studies have revealed 
that virtually every child has been exposed to HMPV by the age of 5 (189). 
Depending on the population analyzed, 5 to 15% of respiratory infections and 12 
to 55% of otitis media may be attributed to HMPV infection (186). Retrospective 
studies have revealed that HMPV is not a new virus, but rather one that has been 
circulating for about 50 years (189). There is currently no effective treatment or 
vaccine available for HMPV infection. Recent studies in mice have revealed an 
important role for T cells in anti-viral immunity and pathogenesis (190), however 
our current understanding of the innate immune response to HMPV is limited.  
HMPV is an enveloped virus, containing a single-stranded negative-sense 
RNA genome, encoding 8 open reading frames. Based on its sequence 
homology to the avian pneumovirus, it was assigned to the Metapneumovirus 
genus within the Paramyxoviridae family, which includes some of the most 
prevalent viruses known (Measles virus, RSV) (173). Phylogenetic analysis has 
revealed two major genetic clusters for HMPV, designated as group A and B, 
which have been further subdivided into four main subtypes A1, A2, B1 and B2 
(186, 187). Unlike most viruses which enter cells by receptor-mediated 
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endocytosis, most paramyxoviruses deliver their genome into the cytoplasm 
directly by fusion with the plasma membrane (164).The attachment (G, H or HN) 
and fusion (F) proteins are critical for mediating these events (191). Most other 
viruses enter cells by receptor-mediated endocytosis and are delivered to the 
endosomal compartment where the acidic environment is critical for viral fusion 
and the release of viral genomes into the cytosol. Several classes of germline 
encoded pattern recognition receptors, which recognize different components of 
viruses, have been identified. In most cases, viruses are sensed via their 
genomes or their replicative or transcriptional activities (192). The recognition of 
RNA and DNA viruses has been shown to involve endosome-localized TLRs, 
including TLR7 and TLR9, which are predominantly expressed on PDC, the 
major producers of IFNα in vivo (90). Both Influenza virus and VSV are sensed 
by TLR7 in PDC (42), whereby recognition of the genomes of these ssRNA 
viruses is tightly linked to viral fusion and uncoating (41). DNA viruses such as 
HSV are sensed in PDC via TLR9. Induction of IFNα by the TLR7/9 pathway is 
mediated by the TLR adapter MyD88 and the transcription factor IRF7 (122, 
193). 
Sensing of RNA and DNA viruses also occurs in the cytosol and in the 
case of RNA viruses, is mediated by a second class of immune sensors, the 
RNA helicases, RIG-I and MDA-5. Genetic evidence has revealed that RIG-I and 
MDA-5 discriminate between different classes of RNA viruses (90, 151). RIG-I is 
required for triggering anti-viral responses against several Flaviviridae, 
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Paramyxoviridae, Orthomyxoviridae and Rhabdoviridae, whereas MDA-5 is 
required for the response against picornaviruses like EMCV (90, 194). RIG-I 
senses the nascent 5’ triphosphate moiety of viral genomes or virus derived 
transcripts of negative-sense ssRNA viruses, whereas MDA5 is activated by long 
dsRNA, a typical intermediate of replication of plus-sense ssRNA viruses. RIG-I 
and MDA-5 induce type I IFN responses by recruiting a CARD domain containing 
adapter molecule, MAVS (83) and triggering IRF3 activation to regulate type I 
IFN gene transcription. Some DNA viruses are also sensed by a pathway 
involving RIG-I, however in this case viral DNA is transcribed by RNA 
polymerase III into an RNA intermediate which is then recognized by RIG-I (101, 
102). 
A recent study has implicated the RIG-I pathway in sensing of the HMPV 
strain CAN97-83 (A2 strain). HMPV CAN97-83 induces IFNβ and chemokine 
gene expression in a RIG-I dependent manner (188). Here, we have examined 
the role of RIG-I in the detection of HMPV viruses by comparing 2 prototype 
strains NL\1\00 (A1) and NL\1\99 (B1) in human primary cells and cell lines. 
Although closely related, only the HMPV-A1 strain activated type I IFN gene 
transcription in most cell types examined. In both human cell lines as well as 
highly purified human monocytes the A1 but not the B1 strain induced type I IFN. 
In these cell types, induction of IFNα/β by HMPV-A1 was mediated by the 
recognition of 5‘-triphosphate viral RNA through RIG-I and its downstream 
adaptor MAVS. In contrast to human cell lines and monocytes, PDC produced 
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type I IFN upon infection with both A1 and B1 strains. In PDC, treatment of cells 
with lysosomotropic agents that prevented endosomal acidification blocked IFNα 
induction by both viruses, which was mediated by TLR7. Taken together these 
data emphasize the unique ability of PDC to sense and induce type I IFN in 
response to viruses that appeared “invisible” to most other cell types. These data 
also indicated that the possibility of two closely related viruses to differentially 
antagonize innate immune sensing mechanisms. 
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Results 
HMPV-A1 can activate IFNB gene in human cell lines and primary cells. 
In an effort to understand the underlying mechanisms regulating the innate 
immune response to HMPV viruses, we tested the ability of 4 major strains (A1, 
B1, A2 and B2) to induce type I IFN by examining IFNβ reporter gene activity in 
infected cells. 293T cells were transfected with a reporter gene under the control 
of the IFNB gene enhancer, and then were infected with the 4 strains of HMPV 
viruses separately. We measured the luciferase value as the readout of IFNβ 
reporter activation. The HMPV-A1 strain induced the IFNβ reporter expression at 
a high level, while the other strains failed to drive this reporter (Figure 2.1a).  
We also observed HMPV-A1 stain activated IFNB gene in the human 
hepatoma cell line, Huh7 (Figure 2.1b) and the human alveolar epithelial cell line, 
A549 (Figure 2.1c). Similar observations were made when the endogenous IFNβ 
transcript levels were measured. HMPV-A1 induced IFNB gene transcription. 
(Figure 2.1d). We also tested IFNα4 reporter and observed that HMPV-A1 strain 
activated this reporter. (Figure 2.1e). In the same experimental conditions, 
HMPV-B1 strains failed to activate type I IFN reporter or transcription in these 
cell lines.  
We also tested the induction of type I response by HMPV viruses in 
primary cells. Human peripheral blood mononuclear cells (PBMC) were purified
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Figure 2.1 HMPV A1 and B1 strains differentially induce type I IFN gene 
expression (a-c, e) 293T, Huh7 or A549 cells were transfected with the full length IFNβ 
promoter or IFNα4 promoter. Cells were infected with HMPV-A1, HMPV-B1, HMPV-A2, 
or HMPV-B2 (from 5x104 to 5x102pfu/ml for 293T, 5x104pfu/ml for other lines) for an 
additional 24h. Data are expressed as fold induction relative to the reporter-only control 
and are the mean ± SD. (d) 293T cells were stimulated with HMPV-A1 or HMPV-B1 
(5.104pfu/ml) for the indicated time. Levels of human IFNβ and β-actin were quantified in 
RNA samples by real-time PCR. Results are presented in arbitrary units as the ratio of 
IFNβ over 100 copies of β-actin. 
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from whole blood and infected with HMPV viruses and the production of the type 
I IFN (IFNα) was measured by Enzyme-linked immunosorbent assay (ELISA). 
Contrary to previous observations in human cell lines, both the HMPV-A1 and 
HMPV-B1 strains induced type I IFN in PBMC (Figure 2.2a). Both IFNα and IFNβ 
mRNA levels were induced as measured by quantitative PCR (Figure 2.2b). 
Monocytes and PDC are the major producers of type I IFN in PBMC. We 
therefore purified monocytes and PDC from total PBMC. Monocytes responded 
to HMPV-A1 but not B1 (Figure 2.2c) while PDC responded to both viruses 
(Figure 2.2d). These results revealed the unique ability of PDC to induce type I 
IFN in response to HMPV-B1, which may signal through a different pathway than 
in cells lines and monocytes. We first focused on HMPV-A1 stain in order to 
investigate the mechanism of type I IFN induction by HMPV in cell lines and then 
used both A1 and B1 strains to study the response in PDC. 
 
HMPV-A1 triggers type I IFN gene transcription via RIG-I/MAVS pathway 
Since RIG-I is a sensor of paramyxoviruses and HMPV has been shown 
to trigger RIG-I signaling (83, 90, 188, 195), we investigated the contribution of 
the RIG-I pathway to IFNB gene activation upon HMPV-A1 stimulation. We first 
examined the role of MAVS, which is the adaptor protein for RIG-I and MDA5 for 
signaling to downstream kinases and transcription factors. The involvement of 
MAVS was assessed using the NS3/4A protease from Hepatitis C Virus (HCV).  
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Figure 2.2 Induction of type I IFN in primary cells in response to HMPV-A1 and B1 
is cell type dependent. (a, c, d) Total PBMC, monocytes or PDC were stimulated with 
HMPV-A1, HMPV-B1 (2x105pfu/ml), CpG-A 2216 (3mM), NDV (8HAU/ml), or 
poly(dAdT)•poly(dAdT) (5mg/ml) for 24h. Protein levels were measured in the 
supernatant of culture by ELISA and presented as the mean ± SD. (b) PBMC cells were 
stimulated with HMPV-A1 or HMPV-B1 (2.105pfu/ml) for 18h. Levels of human IFNα, 
IFNβ and β-actin were quantified in RNA samples by real-time PCR. Results are 
presented in arbitrary units as the ratio of IFNα or IFNβ over 100 copies of β-actin. 
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NS3/4A cleaves MAVS off the mitochondria and inactivates MAVS, thereby 
disrupting RIG-I signaling (196). NS3/4A can therefore be used as a tool to 
implicate MAVS signaling in a particular response. The effect of NS3/4A on the 
HMPV-A1-induced IFN response was tested in 293T cells. Increasing 
concentrations of wild-type (WT) NS3/4A protease dose-dependently blocked the 
induction of IFNβ by HMPV-A1 as well as that induced by SV (Figure 2.3a). 
Importantly, the protease inactive mutant (NS3/4A-S139A) had no effect. The 
results indicated that MAVS is involved in the IFNβ activation pathway in 
response to HMPVA1. 
Then we tested the involvement of RIG-I using the hepatoma cell line 
(Huh7) and the Huh7.5 sub-line that bears a natural mutation in RIG-I (T55I), 
which renders it inactive (197). The transcriptional enhancer of the IFNB gene 
contains four positive regulatory domains (PRDI–IV), which bind distinct 
transcriptional regulators that act cooperatively to activate IFNB gene expression. 
The transcription factors that bind to these elements include NFκB, which binds 
to PRDII; IRF-3 and -7, which bind to adjacent PRDIII and PRDI sites, collectively 
referred to as PRDIII-I, and the heterodimeric transcription factor ATF-2/c-Jun, 
which binds to PRDIV. Huh7 and Huh7.5 cells were transfected with the IFNB-
PRDIII-I (IRF) reporter gene and then infected with HMPV-A1 or NDV. Activation 
of the IFNB-PRDIII-I element was completely abrogated in the Huh7.5 cell line in 
response to HMPV-A1 (Figure 2.3b). The IFNβ response following NDV infection 
(which is known to be RIGI-I-dependent) was also inhibited in the Huh7.5 cells,
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Figure 2.3 HMPV-A1 triggers type I IFN gene transcription via RIG-I/MAVS pathway 
(a) 293T cells were transfected with the IFNβ reporter gene and increasing 
concentrations (5-80ng/well) of the WT or S139A inactive NS3/4A protease from HCV. 
Cells were stimulated for an additional 24h with HMPV-A1 (5x104pfu/ml) or SV 
(400HAU/ml). Data are expressed as fold induction relative to the reporter-only control 
and are the mean ± SD. (b) Parental human hepatoma cell line Huh7 and Huh7.5 were 
transfected with the IFNβ reporter gene in the absence or presence of pEFBos-huRIG-I 
Flag (40ng/well). Cells were stimulated with HMPV-A1 (5x104pfu/ml) or NDV (64HAU/ml) 
for an additional 24h. Results are normalized by renilla luciferase and presented as 
arbitrary units after correction between the 2 cell lines using the pGL3-control. (c) 
Parental human hepatoma cell line Huh7 and Huh7.5 were transfected with the PRDIV 
reporter gene and stimulated with HMPV-A1 (5x104pfu/ml) for an additional 24h. Results 
are normalized by renilla luciferase and presented as arbitrary units after correction 
between the 2 cell lines using the pGL3-control. (d) 293T cells were transfected with 
increasing amounts of RIG-IC (0-2-20ng/well) along with the IFNB reporter and 
stimulated with HMPV-A1 (5x104pfu/ml). Luciferase activity was measured 24h post-
transfection and data are expressed as fold induction relative to the reporter-only control 
and are the mean ± SD. (e) 293T cells were transfected with or without RIG-Ic (2ng/well) 
along with the PRDII or PRDIV element reporter and stimulated with HMPV-A1 
(5x104pfu/ml) for an additional 24h. Luciferase data are expressed as fold induction 
relative to the reporter-only control and are the mean ± SD.   
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consistent with published results. Moreover, reconstitution of Huh7.5 cells with 
WT RIG-I fully restored the response to both HMPV-A1 and NDV. Interestingly, 
IFNB-PRDIV (MAP kinase) reporter gene activation by HMPV-A1 was not 
inhibited in Huh7.5 cells (Figure 2.3c). 
We also found that a dominant negative version of RIG-I, consisting of the 
helicase domain only (RIG-IC), dose-dependently inhibited the IFNβ response in 
293T cells elicited by HMPV-A1 virus (Figure3d). Consistent with the results in 
Huh7.5 cells, IFNB-PRDII (NFκB) and IFNB-PRDIV (MAP kinase) reporter gene 
activation by HMPV-A1 were not inhibited by RIG-IC overexpression in 293T 
cells (Figure 2.3e). Collectively these observations suggest that HMPV viruses 
can trigger RIG-I to turn on type I IFN production and also trigger RIG-I-
independent signaling events leading to NFκB and AP-1 activation. Thus, RIG-I 
as well as additional yet unidentified PRR driven pathways contribute to the host 
response to this virus.  
Although MDA5 also uses MAVS as adaptor protein for downstream 
signaling, MDA5 did not appear to be involved in the recognition of HMPV-A1. A 
dominant negative mutant form of MDA5 did not inhibit the induction of the IFNβ 
reporter by HMPV-A1 (Figure 2.4a left panel), but blocked the IFN response to 
WT MDA5 (Figure 2.4a right panel). A recent paper reported that NOD2 was a 
very early receptor for RSV (belongs to paramyxovirus family, the closest relative 
of HMPV) to trigger IFNβ response in human cell line 293T (198). In our hands, 
overexpression of RIG-I but not NOD2 in 293T cells enhanced the induction of
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Figure 2.4 Type I IFN activation by HMPVA1 does not involve MDA5 or NOD2 (a) 
293T cells were transfected with the IFNβ reporter gene and WT or a dominant negative 
mutant of MDA-5 (80 ng/well). Cells were stimulated with HMPV-A1 (5x104pfu/ml) for 
additional 24hrs. Data are expressed as fold induction relative to the reporter-only 
control and are the mean ± SD. (b) 293T cells were transfected with IFNB reporter gene 
and indicated NOD1, NOD2, or RIG-I expression plasmids (40ng/well). Cells were 
stimulated with HMPVA1 (5x104pfu/ml) or RSV A2 strain (5x104pfu/ml) for additional 
6hrs (left panel) or 10hrs (right panel). Data are expressed as fold induction relative to 
the reporter-only control and are the mean ± SD. 
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IFNβ luciferase activity by HMPV-A1 and RSV even at early time points. The 
results suggested a major role for RIG-I in the sensing of those viruses and 
NOD2 did not seem to be involved in this response (Figure 2.4b).  
We next examined the requirement for viral replication in the HMPV-A1 
induced type I IFN response. We compared live virus to either heat or UV-
inactivated HMPV-A1 on IFNβ reporter gene activity in 293T cells. UV- and heat-
inactivation of HMPV-A1 and NDV completely blocked their ability to induce 
IFNB reporter gene activity (Figure 2.5a). Similar results were observed in 
purified human monocytes, the activation of IFNα was totally lost (Figure 2.5b).  
The 5'-triphosphate moiety of the viral RNA is the major ligand recognized by 
RIG-I (178, 199). To further investigate the nature of the ligand in HMPV viruses 
that triggers RIG-I, viral RNA was purified from HMPV-A1 and transfected into 
the cytoplasm of 293T cells using lipofectamine. Transfection of the viral RNA 
induced the IFNβ reporter gene and removal of the phosphate groups by calf 
intestinal alkaline phosphatase (CIAP) or digestion of the viral RNA by RNAse A 
abrogated this response (Figure 2.5c). IFN induction by the double stranded DNA 
analog, poly(dA-dT)·poly(dA-dT), was unaffected by either CIAP or RNAse A 
treatment. Moreover, RIG-IC also dose-dependently inhibited the IFNβ response 
in 293T cells elicited by either HMPV-A1 virus or by HMPV-A1 viral RNA (Figure 
2.5d). These data indicate that 5’-triphosphate RNA is the ligand for RIG-I. 
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Figure 2.5 Induction of IFNβ  by HMPV-A1 requires viral replication.  (a) 293T cells 
were transfected with the full length IFNβ promoter. Cells were stimulated 24h later with 
live, UV- or heat-inactivated HMPV-A1 (2x105pfu/ml) or NDV (8HAU/ml) for an additional 
24h. Data are expressed as fold induction relative to the reporter-only control and are 
the mean ± SD. (b) Freshly isolated monocytes were stimulated for 24h with live, UV- or 
heat-inactivated HMPV-A1 (2x105pfu/ml) or NDV (8HAU/ml). Human IFNα protein levels 
were measured in the supernatant of culture by ELISA and presented as the mean ± SD. 
(c) 293T cells were transfected with viral RNA purified from HMPV-A1 (80ng) or 
poly(dAdT)•poly(dAdT) (20ng) along with the IFNβ and TK-renilla reporter genes. vRNAs 
and poly(dAdT)•poly(dAdT) were treated with calf intestinal alkaline phosphatase (CIAP) 
or RNAse A prior to stimulation as indicated. (d) 293T cells were transfected with 
increasing amounts of RIG-IC (0-2-20ng/well) along with the IFNB reporter and vRNAs 
(80ng), or stimulate with HMPV-A1 (5x104pfu/ml). In all cases, luciferase activity was 
measured 24h post-transfection and data are expressed as fold induction relative to the 
reporter-only control and are the mean ± SD. 
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Detection of HMPV viruses in PDC does not involve RIG-I but occurs via an 
endosomal sensing pathway 
As shown in Figure 1, both A1 and B1 strains induce type I IFN production 
in PDC. The studies outlined above indicate that it is possible that besides RIG-I 
others receptors mediated these events. Quantitative PCR analysis revealed that 
PDC express RIG-I and MAVS albeit at much lower levels than that found in 
monocytes (200). To examine the contribution of the RIG-I pathway in PDC 
responses to HMPV viruses, we monitored PDC from mice lacking MAVS. PDC 
from MAVS-deficient mice responded normally to both HMPV viruses (as well as 
to NDV, HSV and Influenza viruses) (Figure 2.6a). These latter three viruses 
have been shown to signal in PDC via TLRs (see below). R848 and CpG DNA, 
ligands for TLR7 and TLR9 respectively, also induced IFNβ normally in MAVS-
deficient PDC. Of note MAVS-deficient myeloid DCs or macrophages are 
severely compromised in NDV induced IFN responses (Figure 2.6b).  
In order to define the mechanisms sensing these viruses in human PDC, 
we investigated the requirement for viral replication in mediating these 
responses. In contrast to our observations in 293T and monocytes (Figure 
2.5a,b), UV- and heat-inactivation of HMPV-A1, B1 and NDV only partially 
affected their ability to induce IFNα production (Figure 2.6c). Altogether, these 
studies confirmed that sensing of HMPV viruses in PDC is not mediated via the 
RIG-I cytosolic pathway.  
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Figure 2.6 Induction of type I IFN in PDC in response to both HMPV-A1 and B1 is 
through endosomal pathway. (a). PDC from C57Bl6/129 and MAVS-/- mice were 
stimulated for 24h with CpG-A (2mM), Heat-inactivated Influenza (MOI=0.1), HSV 
(MOI=100) HMPV-A1, HMPV-B1 (2x105pfu/ml). Mouse IFNβ protein levels were 
measured in the supernatant of culture by ELISA and presented as the mean ± SD. (b). 
BMDM and BMDCs from C57Bl6/129 and MAVS-/- mice were stimulated 24h with 
PolydAdT (5-2.5ug/ml) or NDV (32-3.2HAU). Mouse IFNβ protein levels were measured 
in the supernatant of culture by ELISA and presented as the mean ± SD.  (c). Freshly 
isolated PDC were stimulated for 24h with live, UV- or heat-inactivated HMPV-A1, 
HMPV-B1 (2x105pfu/ml) or NDV (8HAU/ml). Human IFNα protein levels were measured 
in the supernatant by ELISA and presented as the mean ± SD. (d-e). Freshly isolated 
PDC and monocytes were stimulated with HMPV-A1, HMPV-B1 (2x105pfu/ml), NDV 
(8HAU/ml), Heat-inactivated Influenza (MOI=0.1), CpG-A (2mM) for 24 hours. Cells were 
pre-incubated with chloroquine (1mM) or bafilomycin A1 (4mM for PDC, 10mM for 
monocytes) for 1 hour were indicated. Human IFNα protein levels were measured in the 
supernatant by ELISA and presented as the mean ± SD.  
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Since PDC express high levels of TLR7 and TLR9 and sense viruses via 
endosomally localized TLRs, we next examined the role of this system in the 
detection of HMPV-A1 and B1 viruses. PDC were treated with chloroquine or 
bafilomycin A1, two lysosomotropic agents that act by raising the intra-
endosomal pH or by specific inhibition of the vacuolar ATPase, respectively (201) 
(41). Induction of IFNα by HMPV-A1 and B1 in PDC was totally abrogated when 
cells were pretreated with either chloroquine or bafilomycin A1 (Figure 2.6d). 
Responses to CpG-A were also completely blocked by chloroquine and 
bafilomycin A1, consistent with published results (201). In contrast to PDC 
responses, induction of IFNα by HMPV-A1 in monocytes was less affected 
(Figure 2.6e). IFNα Induction in response to Influenza is presumably down in 
chloroquine or bafilomycin A1 treated conditions because of a failure of the virus 
to infect. 
For viruses that enter cells by receptor-mediated endocytosis, viral fusion 
and uncoating events are tightly coupled to recognition of viral ligands by 
endosomally localized TLRs. Therefore, inhibition by chloroquine and bafilomycin 
could implicate TLRs in the sensing of these viruses. To examine the precise role 
of endosomal TLRs in the recognition of A1 and B1 viruses, PDC were isolated 
from WT, TLR7 and TLR9-deficient mice and examined IFNβ secretion post-virus 
infection. As expected, induction of IFNβ by CpG-A and HSV1 was entirely 
dependent on TLR9 (Figure 2.7a). In contrast, IFNα induced in response to 
Influenza was unaffected in TLR9-deficient PDC but was completely defective in 
66
TLR7-deficient PDC. HMPV-A1 and -B1 IFNβ production in PDC was induced 
normally in TLR9-deficient PDC and fully impaired in TLR7-deficient PDC. We 
also confirmed the TLR7 dependency in the human system using ISS661, a 
previously characterized oligonucleotide-based inhibitors for TLR7 signaling (48). 
Pre-treatment with ISS661 blocked the induction of IFNα by HMPV-A1 and B1 
(Figure 2.7b). Pretreatment with CpG2088, an inhibitor of TLR9 signaling (202, 
203) had no effect. These results reveal that the unique ability of PDC to induce 
type I IFN in response to HMPV-B1 correlates with the sensing of HMPV viruses 
through TLR7, and not the cytosolic RNA helicase pathway. 
67
 
 
Figure 2.7 Induction of type I IFN in PDC in response to both HMPV-A1 and B1 is 
TLR7-mediated. (a). Mouse PDC from C57Bl6, TLR7-/- and TLR9-/-mice were 
stimulated for 24h with CpG-A (2mM), Heat-inactivated Influenza (MOI=0.1), HSV 
(MOI=100) HMPV-A1, HMPV-B1 (2x105pfu/ml). Mouse IFNβ protein levels were 
measured by ELISA and presented as the mean ± SD. (b) Freshly isolated PDC were 
stimulated with HMPV-A1, HMPV-B1 (2x105pfu/ml), R848 (10nM), CpG-A (2mM) for 24 
hours. Cells were pre-incubated with CpG2088 (0.1mM) or ISS661 (2mM) for 1 hour 
were indicated. Human IFNα protein levels were measured in the supernatant by ELISA 
and presented as the mean ± SD.  
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Discussion 
HMPV and RSV viruses are major contributors to respiratory tract 
infections in infants and young children. In most infants, these viruses cause 
symptoms resembling those of the common cold. However, in infants born 
prematurely, children with chronic lung disease, or children with congenital heart 
disease, these viruses can result in a severe or even life threatening disease. As 
many as 125,000 hospitalizations occur annually in children less than one year 
old due to lower respiratory infection or bronchiolitis (204). Developing new 
therapeutics to prevent and treat these infections is therefore of considerable 
importance. 
Limiting virus infection requires rapidly mounted defences, which include 
in large part the release of type I IFN (IFNα/β). Interferon limits viral replication 
directly and enhances viral clearance by activating adaptive immunity. 
Understanding how viruses are sensed and how type I IFN is regulated may 
facilitate the rational design of novel anti-viral therapeutics and/or better vaccine 
candidates useful in the prevention or treatment of lower respiratory tract 
infections in children. In this study, we demonstrate that type I IFN production 
during infection with HMPV viruses involves differential sensing mechanisms, 
which work in a cell-type specific manner. Sensing of HMPV-A1 virus occurs via 
the cytosolic RNA helicase RIG-I in most cell types, with the exception of PDC. A 
recent study by Casola and colleagues also implicated RIG-I in the sensing of 
HMPV in airway epithelial cells (188). We have confirmed these observations 
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using mice with targeted deletions in the RIG-I pathway and have extended these 
studies to include an analysis of additional cell types. We have identified 5’- 
triphosphate RNA as the HMPV viral ligand triggering the RIG-I-IFNβ response. 
Importantly, we also identified a RIG-I-independent pathway for sensing HMPV-
A1 and B1 viruses in epithelial cell lines. HMPV-A1 and B1 viruses activated 
NFκB and AP-1 dependent reporter genes in a RIG-I independent manner. 
These data suggest additional mechanism of HMPV sensing. The NLR family 
member, NOD2 was recently shown to act as a cytosolic sensor for RSV 
infection (198), while our preliminary results suggested that NOD2 is not a 
receptor sensing HMPV for type I IFN production. However, further studies are 
required to properly delineate if NOD2 or other receptors also senses HMPV and 
especially towards NFκB and AP-1 signalling described herein.  
In this study we also compared the innate response to two closely related 
clinical viral isolates. While only HMPV A1 strain elicit a type I IFN response in 
monocytes and all the cell lines tested and the B1 strain failed to do that, both 
strains induced type I IFN responses in PDC. IFN production induced by both 
HMPV strains in PDC was sensitive to bafilomycin A1 and chloroquine and was 
dependent on TLR7. The current model of anti-viral sensing in PDC suggests 
that TLR-mediated recognition of viruses occurs without direct infection and that 
the presence of viral genomic nucleic acids within the endosomal/lysosomal 
compartment is sufficient to trigger TLRs. Iwasaki and colleagues demonstrated 
recently that RNA viruses such as VSV which do not enter cells via the 
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endosomal compartment but replicate in the cytosolic compartment where 
cytosolic viral replication intermediates are then delivered into the lysosomal 
compartment by the process of autophagy to trigger TLRs (166). Our preliminary 
data assessing the role of autophagy in the recognition of HMPV viruses in PDCs 
showed that induction of IFNα by PDC in response to both HMPV strains, as well 
as VSV as previously published was abrogated by 3-methyladenine and 
wortmannin pretreatment. These data suggest that viral RNA may be delivered to 
TLR7 in the endosome via autophagy.  
Generally cell entry of paramyxoviruses requires two glycoproteins: the 
attachment (G, H or HN) and fusion (F) proteins. In the case of HMPV viruses, 
however, analysis of recombinant viruses lacking the G protein has suggested 
that attachment and fusion is mainly dependent on the F protein (205). The F 
protein is a type I glycoprotein, synthesized as an inactive precursor, F0 and 
subsequently converted into its biologically active form, the heterodimer F1/F2. 
The majority of Paramyxoviridae F proteins are cleaved intracellularly by host 
cellular proteases, most notably furin. Cleavage of the F-protein from HMPV 
however, requires secretory proteases, which restrict HMPV viruses to the lumen 
of the respiratory and enteric tract for replication in vivo. In vitro the addition of 
trypsin to process the F0 protein into its mature form allows efficient propagation 
of the virus (206). In contrast to most other Paramyxoviridae F proteins that 
require neutral pH for membrane fusion, cleavage of the HMPV F protein might 
therefore require low pH conditions (175). These findings might indicate a 
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requirement for low-pH compartments such as the endosome for entry of HMPV 
viruses in PDC. Receptor-mediated endocytosis at low pH was indeed recently 
shown in Vero cells for HMPV-A2 strain (207). Since PDC do not need to be 
infected to induce type I IFN, the ability of PDC to respond may be a result of 
uptake of viral particles to the endosome directly.  
Altogether, our data unveil 2 different mechanisms for sensing of HMPV 
viruses in the host. Such cell type specific involvement of the RIG-I versus TLR 
pathways in induction of antiviral responses is not unique to HMPV viruses. This 
differential sensing has previously been reported in the case of sensing of NDV 
(151). One can imagine how important it is that more than one mechanism exists 
to turn on IFN gene regulation. This is particularly important in situations where 
pathogenic viruses inactivate the IFN arm of the immune response. By employing 
more than on strategy to turn on IFN, the host allows a back up plan should one 
arm be deactivated. Defining the role of the RLRs and TLRs in sensing HMPV 
provides a framework for understanding the evolutionary pressures on the host to 
constantly evolve mechanisms that are able to overcome viruses’ ability to 
dampen protective responses. Such an understanding of how viruses are 
detected is essential for the development of vaccines to harness the power of the 
innate immune system for the benefit of the host.  
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Material and methods 
Cells and mice.  
HEK 293, 293T, alveolar epithelial cells (A549) and Vero cells were from 
ATCC (Manassas, VA). The human hepatocellular carcinoma cell lines Huh7 and 
Huh7.5 were from C. Rice (Rockefeller University, New York, NY). B16-FLT3L 
producing cells were from G. Dranoff (HMS, Boston, MA) (208). All of the above 
cell lines were maintained in DMEM (Mediatech Inc, Herndon VA) supplemented 
with 5% FBS (Hyclone, Logan UT) and 10mg/ml Ciprofloxacin (Mediatech Inc). 
C57/Bl6 and C57/BL6-129 F1 mice were from Jackson Laboratories (Bar Harbor, 
ME). MAVS–/– mice on a mixed C57/BL6x129 background were from Z.J. Chen 
(UT Southwestern, Dallas, TX). TLR7–/– and TLR9–/– mice were from S. Akira 
(Osaka University, Osaka, Japan). Animal studies have been reviewed and 
approved by the University of Massachusetts Medical School institutional animal 
care and use committee. 
Reagents 
The HMPV viral isolates A1 (NL\1\001), B1 (NL\1\99), A2 (N\L\00\17) and 
B2 (N\L\94\01) were provided by Medimmune Inc. (Gaithersburg, MD) and were 
propagated as previously described in IMDM 4% BSA trypsin (206, 209). 
Influenza virus (strain A/PR/8/34) was from Charles River Laboratories (Boston, 
MA). NDV (LaSota strain) was from P. Pitha (Johns Hopkins, Baltimore, MD). 
HSV-1 (KOS strain) was from D. Knipe (HMS, Boston, MA). HMPV and NDV 
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were inactivated by heating at 56°C for 30 min or by UV cross-linking at a dose of 
2 Joules/cm2. RSV A2 strains was from Medimmune Inc. (Gaithersburg, MD). 
CpG-A (CpG 2216), CpG 2088 (48) and ISS661 (203) were from IDT (Coralville, 
IA). Poly (dA-dT)•Poly (dA-dT) was from GE Healthcare (Piscataway NJ). 
Chloroquine, and Bafilomycin A1 were from Sigma-Aldrich (St. Louis, MI).  
Plasmids 
The IFNβ luciferase, pGL3-PRDII, -PRDIII-I and -PRDIV luciferase 
reporter genes were from T. Maniatis (Harvard, Cambridge, MA). The IFNα4 
luciferase reporter gene was from S. Akira (Osaka, Japan). Human RIG-I flag 
and RIG-IC (helicase domain only) were from T. Fujita (Tokyo, Japan). A 
dominant negative mutant form of MDA5 (MDA5-T789M) was from D. Conte (C. 
Mello Lab, UMASS Medical School, Worcester, MA). pME18-NS3/4A-myc and 
pME18-NS3/4A-S139A-myc were from Z.J. Chen (UT Southwestern, Dallas, 
Texas). NOD1 and NOD2 plasmids are from Dr. Nunez (U of Michigan Medical 
School, Ann Arbor, MI) pGL4-TK renilla luciferase and pGL3-control luciferase 
were from Promega (Madison, WI).  
Mouse and human primary cell isolation 
Human PBMC were freshly isolated by density-gradient centrifugation 
using Ficoll Hypaque (GE Healthcare). Monocytes and PDC were purified from 
PBMC using CD14 microbeads and the diamond PDC isolation kit respectively 
as recommended by the manufacturer (Miltenyi Biotec). Purity of these 
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populations was assessed by staining for CD14 and BDCA2 expression by flow 
cytometry, and was greater than 95%.  Mouse PDC were purified from spleens of 
mice injected with BL6-FLT3L producing cells.  Briefly, mice were injected 
subcutaneously with 5 x 106 cells in 300µl PBS. Spleens were harvested within 2 
weeks after injection and PDC were isolated using the PDC isolation kit II 
(Miltenyi Biotec). Purity was assessed by staining for CD11c, Ly6C and mPDCA1 
expression by flow cytometry, and was greater than 85%.  
Reporter assays  
Luciferase reporter assays were conducted as previously described (95). 
Briefly, 293T cells or A549 cells (2.104 cells/well in 96-well plates) were 
transfected with the indicated luciferase reporter genes together with TK Renilla-
luciferase reporter gene and with of the indicated expression plasmids using 
Genejuice (Novagen, Madison, WI). Luciferase activity was measured as 
previously described (210). Huh7 and Huh7.5 cells (4.104 cells/well in 96-well 
plates) were transfected as above except that these cells were also transfected 
with 40ng of a pGL3 control reporter, which drives constitutive luciferase activity 
in order to normalize the data between the two cell lines. Data were normalized 
according to manufacturer recommendations (Promega).  
Viral RNA Purification 
Viral RNA from HMPV-A1 and B1 was extracted using the QIAamp viral 
RNA mini kit (Qiagen, Valencia, CA). Viruses were concentrated by 
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ultracentrifugation for 2h at 4 °C at a speed of 27,000 RPM using a SW28 rotor 
(Beckman, CA). RNA (1.5mg) was treated with or without 10U of calf intestinal 
alkaline phosphatase (CIAP, Fermentas) for 3h at 37°C or RNase A (Promega) 
for 1h at 37°C. All samples were then treated for 15min at 85°C to inactivate the 
enzymes. Viral RNA was transfected into 293T cells using lipofectamine 2000 at 
a ratio 1:1 (weight/volume) along with the IFNβ luciferase and the TK-renilla 
reporter genes according to the manufacturer instructions (Invitrogen).  
ELISA 
For ELISA analysis, human PBMC (2.105/well), monocytes (1.105/well) 
and PDC (4.103/well), or mouse PDC (5.104/well) were plated in 96 well plates in 
100 ml and stimulated for 24h. Poly (dA-dT)•poly (dA-dT) was transfected as 
previously described (211) at 5ug/ml using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) at a ratio 2:1 (weight/volume). Human IFNα was measured 
according to the manufacturer’s recommendations (Bender Medsystems, 
Burlingame CA). A murine IFNβ sandwich ELISA was used as previously 
described (212).  
RNA extraction and real time PCR 
293T cells (2.106cells per 10 cm plate) were stimulated with HMPV-A1 or 
HMPV-B1 (3.2.105pfu/ml) for 5 to 48h and RNA isolated using RNeasy (Qiagen, 
Valencia CA). cDNA were synthesized as previously described (95) using the 
SuperScript III enzyme (Invitrogen). Quantitative real-time PCR analysis was 
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performed using SYBR green reagent (Invitrogen) on a DNA engine Opticon 2 
cycler (Bio-Rad, Hercules CA) using the following primers: IFNβ-F 
CAGCAATTTTCAGTGTCAGAAGC; IFNβ-R CATCCTGTCCTTGAGGCAGT; 
IFNα-F GTGAGGAAATACTTCCAAAGAATCAC; IFNα-R 
TCTCATGATTTTCTGCTCTGACAA; β−actin-F CCTGGCACCCAGCACAAT; 
β−actin-R GCCGATCCACACGGAGTA. The specificity of amplification was 
assessed for each sample by melting curve analysis, and the size of the 
amplicon checked by electrophoresis. PCR efficiency was calculated for both 
vRNA with ten-fold dilutions of the cDNA with the formula E = 10[–1/slope]-1 as 
previously described (213). Relative quantification was performed using standard 
curve analysis. All gene expression data were normalized with β-actin and are 
presented as a ratio of gene copy number per 100 copies of β -actin +/-SD. 
Statistical analysis 
Differences between groups were analyzed for statistical significance by 
using a t-test in Prism software. P<0.05 was considered statistically significant. 
***,  ** and * represent p values of <0.001, <0.01 and <0.05, respectively. 
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Chapter III Interference with type I IFN production by HMPV 
 
Abstract 
Acute viral infection activates a type I IFN antiviral response that is 
essential for curbing viral replication until adaptive immunity clears the virus. 
Usurping IFN induction pathways is a common tactic employed by viruses to 
enable their replication within host cells. Our previous study showed the 
differential induction of type I IFN by two closely related HMPV strains. Both 
viruses were able to infect and replicate and the naked viral RNA of both could 
trigger RIG-I if delivered by lipofection into the cytoplasm, however in contrast to 
HMPVA1 virus, the live HMPVB1 virus failed to activate RIG-I. The data suggests 
that the B1 virus interferes with the RIG-I dependent type I IFN signalling 
pathway. Although many reports have shown that non-structural proteins from 
paramyxoviruses block type I IFN signalling, it is still not clear how HMPV evades 
IFN inducing pathways. The major focus of this study was to understand the 
mechanism underlying the inability of HMPVB1 virus to trigger type I IFN 
production. The failure of the HMPV-B1 strain to elicit type I IFN production was 
dependent on the B1 phosphoprotein, which specifically prevented RIG-I-
mediated sensing of HMPV viral 5’ triphosphate RNA. Our data unveil a new 
strategy of HMPV virus to interfere with host innate defence. 
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Introduction  
Innate responses against virus infection is initiated by the recognition of 
viral pathogens by PRRs such as TLRs and RLRs, which drive signalling and 
turn on anti-viral gene expression to limit virus infection by rapidly mounted 
defences including in large part the release of type I IFN (IFNα/β). Interferon 
limits viral replication directly and enhances viral clearance by activating adaptive 
immunity. In the previous chapter, we demonstrated that type I IFN production 
during infection with HMPV viruses involves differential sensing mechanisms, 
which work in a cell-type specific manner. While both HMPV-A1 and HMPV-B1 
strains can trigger type I IFN production in PDCs, only the HMPV-A1 strain 
activated type I IFN gene transcription in most cell types examined although 
these two strains are closely related. In PDCs, HMPVA1 and B1 strains are 
sensed by TLR7 to trigger type I IFN production. In contrast in various human cell 
lines as well as primary human monocytes, the induction of type I IFN by HMPV-
A1 was mediated by the recognition of 5’triphosphate viral RNA through RIG-I 
and its downstream adaptor MAVS. In these cell types, type I IFN was not 
induced by HMPVB1 strain, which implies that the RIG-I/MAVS pathway is not 
activated or is inhibited by this strain.  
HMPV belongs to the family of paramyxoviruses, which contains single-
negative-strand RNA viral genome that is considered as good type I IFN 
inducers. Some of them such as SV and NDV are usually used in the laboratory 
as a tool for experimental type I IFN induction. In order to survive, 
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paramyxoviruses developed a variety of strategies to escape the detection and 
antiviral response of the host, especially to counteract the strong and direct 
antiviral activity of type I IFN. By using the viral non-structural proteins encoded 
by their small genome, paramyxoviruses can inhibit type I IFN signaling. Besides 
coding the phosphoprotein P protein that is the essential component of viral 
polymerase complex, P gene also has overlapping open reading frames that give 
multiple distinct protein products, such as “V”, “C’’, “W”, “D”, or “I” proteins by the 
process called “RNA editing”. These alternative P gene products are not 
essential for viral replication but the deletion of these products results in severe 
attenuation associated with the failure to control type I IFN of the host (214). For 
example, the V protein targets STAT protein for the inhibition of IFN signaling. 
Parainfluenza virus 5 V protein was shown to mediating STAT1 degradation 
(215). However, in the Pneumovirinae subfamily that HMPV belongs to, the P 
gene only encodes one protein. The closest relative to HMPV, RSV, has been 
reported to use non-structural (NS)-1 and NS2 proteins to inhibit type I IFN 
signaling pathway by targeting STAT2 protein (216). HMPV stain CAN97-83 was 
shown to interfere with IFN signaling in lung epithelial cells by inhibiting STAT1 
phosphorylation (217). But this strain has also been shown to phosphorylate 
STAT1 (218). Thus the interference with type I IFN by HMPV is still not clear.  
In this chapter, we explored the mechanisms underlying the failure of the 
HMPVB1 viral strain to trigger type I IFN in human cell lines in order to 
understand the evasion of type I IFN system by this virus. We found that the B1 
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strain antagonizes IFN production through the P phosphoprotein. In the context 
of the virus, the HMPV-B1 phosphoprotein prevented RIG-I from sensing the viral 
genome during infection, which is a newly described strategy that HMPV 
employs to subvert viral clearance. 
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Results 
The HMPV-B1 virus fails to activate type I IFN in human cells lines as well 
as human monocytes.  
As shown in data above, both HMPV-A1 and B1 strains induce type I IFN 
production in PDC through TLR7 (Figure 2.2d and 2.6e), while in human 
embryonic kidney (HEK) 293T cells and monocytes only A1 activates the IFNB 
reporter (Figure 2.1a, 2.2c). We then closely investigated the mechanism 
underlying the difference between these two closely related strains A1 (NL\1\00) 
and B1 (NL\1\99). We found that besides 293T cells, HMPV-B1 strain failed to 
induce IFNβ reporter gene activity in the other cell lines we tested such as Huh7 
and A549 (Figure 2.1b,c). The HMPV-B1 strain also failed to induce IFNα4 
reporter gene (Figure 2.1e). Similar observations were made when the 
endogenous IFNβ transcript levels were measured in infected 293T cells. HMPV-
A1 induced IFNB gene transcription while HMPV-B1 failed to do so (Figure 2.1d).   
To exclude the possibility that the failure of the B1 virus to induce type I 
IFN induction was due to a failure to infect or replicate in these cells, we first 
compared viral infection and replication in both monocytes and PDC. Upon 
infection with paramyxoviruses, the viral F protein is first synthesized as an 
inactive precursor F0, which is subsequently converted into the fusogenic F1 
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form by cellular proteases (219). A HMPV-specific anti-F antibody has been 
characterized previously and shown to detect both F0 and F1 forms of the F 
protein from both A1 and B1 strains (209). The level of F-protein expression was 
monitored in infected cells by flow cytometry. Similar percentages of purified 
monocytes (about 20% of CD14+ cells) and PDC (about 45% of BDCA-2+ cells) 
expressing the F protein were observed for both HMPV strains (Figure 3.1a). 
This indicated that both strains can infect these cell types.   
In 293T cells, comparable levels of expression of the F protein (both F0 
and F1 forms) were detected in both HMPV-A1 and B1 infected 293T cells when 
examined by western blotting (Figure 3.1b). We excluded that the staining 
detected might originate from the initial inoculums since no signal was detected 
at 2h post-infection. The amount of F proteins from both A1- and B1-infected  
cells were increasing at comparable pace with longer incubation of viruses with 
infected cells, which indicated the A1 and B1 viruses replicated inside 293T cells 
at a similar rate. Replication of HMPV-A1 and B1 was also examined by 
quantifying the level of viral transcripts and measuring viral titers in infected cells. 
To ensure similar PCR efficiency for both strains, the primer-binding sites were 
designed in a region of the gene encoding the L protein, which was identical in 
both strains. Equivalent levels of A1 and B1 transcripts were detected in infected 
cells throughout the course of infection (Figure 3.1c). Viral titers were also 
equivalent for both strains (Figure 3.1d). This was also true in 293T, A549 and 
Huh7 cells (Figure 3.1e). Indeed, the levels of B1 virus exceeded that of A1 strain 
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Figure 3.1 HMPV-A1 and HMPV-B1 infect and replicate in primary cells and cell 
lines. (a) Purified monocytes (6x105 cells/well) and PDC (2.105 cells/well) were cultured 
for 24h in presence of HMPV-A1 and B1 (3.2x105pfu/ml). Cells were harvested and 
stained for specific cell surface antigen (CD14 or BDCA2) and F protein expression 
using an anti-F biotinylated antibody and PE or APC-conjugated steptavidin. Results are 
presented as histogram overlays of anti-F antibody staining versus isotype control. 
Displayed percentages were substracted from the isotype control. (b). Infection of 293T 
cells by HMPV was assessed by immunoblot analysis. Cells (6x105cells/well) were 
infected with HMPV-A1 or HMPV-B1 (5x104pfu/ml) for 2 to 48h. A specific anti-F 
biotinylated antibody and HRP-conjugated steptavidin were used to detect F protein in 
cell lysates. F0 and F1 forms of the F protein are indicated by an arrow. Anti-F #338 
neutralizing antibody was used to show the specificity. The lower panel shows β-actin 
levels in the samples. (c) Replication of HMPV in 293T was quantified by real-time PCR. 
Cells were infected with HMPV-A1 or HMPV-B1 (5x104pfu/ml) for the indicated time 
points. Levels of HMPV-L gene and human β-actin were quantified in RNA samples 
using specific primers. Results are presented in arbitrary unit as the ratio of HMPV-L 
gene over 100 copies of β-actin. (d-e) Virus titers were determined after infection of 
several cell types (3x105/well) with HMVPA1 or B1 strain (105pfu/ml). Virus titers were 
measured for the indicated time points after infection in Vero cells (d) or after 24h post 
infection in 293T, A549 and Huh7 cells (e) and presented as pfu/ml. 
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at the time point, probably because A1 virus activated the expression of antiviral 
type I IFN. We conclude therefore from these studies, that both viruses infect and 
replicate in all cells tested, however PDC were unique in their ability to induce 
type I IFN in response to HMPV-B1. 
 
The HMPV-B1 virus fails to activate Interferon Regulatory Factor-3.  
Then we test all the positive regulatory domains of the IFNB gene 
transcriptional enhancer using PRDIII-I (IRF), PRDII (NFκB) and PRDIV (MAP 
Kinase) reporters. Only A1 strain activated the PRDIII-I reporter gene, which 
responds to IRF3 and 7 (Figure 3.2a). We also monitored activation of a reporter 
gene containing multimerized ISRE elements from the ISG-54 promoter. 
Consistent with a failure to induce the PRDIII-I element from the IFNB promoter, 
HMPV-B1 virus also failed to drive the ISG54-ISRE (Figure 3.2b). In contrast, 
both HMPV-A1 and B1 induced the PRDII/NFκB and PRDIV/ATF2/c-jun reporter 
genes (Figure 3.2c and d).  
We next monitored endogenous IRF3 activation by examining the 
formation of IRF3 dimers in virus-infected cells. IRF3 is normally present in the 
cytoplasm of resting cells as a monomer. Virus infection triggers the 
phosphorylation and dimerization of IRF3 followed by its nuclear translocation. 
Infection of 293T cells with HMPV-A1 induced IRF3 dimerization in a manner 
similar to that observed with NDV, our positive control (Figure 3.2e). In contrast,
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Figure 3.2 Differential activation of IRF3 by the HMPV A1 and B1 strains. (a-d, f) 
293T cells were transfected with the IFNB PRDIII-I, ISG54-ISRE, PRDII, PRDIV or Gal4 
reporter genes as detailed in Material and Methods. Cells were infected with HMPV-A1 
or HMPV-B1 (range from 5x104 to 5x102pfu/ml, 5x104 pfu/ml for ISRE reporter, 5x104 to 
5x103pfu/ml for Gal4 reporter) for an additional 24h. Data are expressed as fold 
induction relative to the reporter-only control and are the mean ± SD. (e) A549 cells were 
stimulated with viruses for the indicated period of time. Nuclear protein were extracted 
and analyzed by native PAGE. The monomer and dimeric forms of IRF3 are indicated by 
arrows.  
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 cells infected with the HMPV-B1 strain failed to lead to dimerization of 
endogenous IRF3. These observations were confirmed using an in vitro assay for 
IRF3 and IRF7, which utilizes a hybrid protein consisting of the yeast Gal4-DBD 
fused to IRF-3 or IRF-7 lacking its own DBD (220).  Reporter gene expression 
from the Gal4 upstream activation sequence in this assay requires IRF activation 
(220). HMPV-A1 but not B1 activated both the Gal4-IRF3 and IRF7 reporters 
(Figure 3.2f). Taken together these data provide clear evidence that the B1 strain 
fails to trigger IRF3/7 activation and as a result fails to trigger IFNβ production. 
 
The HMPV-B1 P protein prevents sensing by RIG-I.  
We next traced back upstream the RIG-I/MAVS pathway to understand 
the differential responses of the human cells lines to HMPVA1 and B1 strains.  
As shown in the data above, the 5'-triphosphate viral RNA of HMPVA1 is the 
ligand recognized by RIG-I. We wanted to know if the vRNA of HMPVB1 was 
also recognized by RIG-I. The viral RNA was purified from HMPV-B1 and 
transfected into the cytoplasm of 293T cells via lipofection. Similar results were 
observed as using HMPVA1 viral RNA, transfection of the viral B1-RNA induced 
the IFNB reporter gene and removal of the phosphate groups by CIAP or 
digestion of the viral RNA by RNAse A abrogated this response (Figure 3.3a). 
Moreover, RIG-IC also dose-dependently inhibited the IFNβ response in 293T 
cells elicited B1 viral RNAs (Figure 3.3b). These data revealed that the naked
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Figure 3.3 IFNB gene can be activated by vRNA from both HMPV-A1 and B1 
viruses via RIG-I. (a) 293T cells were transfected with viral RNA purified from HMPV-A1 
or B1 (80ng), or poly(dAdT)•poly(dAdT) (20ng) along with the IFNβ and TK-renilla 
reporter genes. vRNAs and poly(dAdT)•poly(dAdT) were treated with calf intestinal 
alkaline phosphatase (CIAP) or RNAse A prior to stimulation as indicated. luciferase 
activity was measured 24h post-transfection and data are expressed as fold induction 
relative to the reporter-only control and are the mean ± SD. (b) 293T cells were 
transfected with increasing amounts of RIG-IC (0-2-20ng/well) along with the IFNB 
reporter and vRNAs (80ng), or stimulate with HMPV-A1 (5x104pfu/ml). Luciferase activity 
was measured 24h post-transfection and data are expressed as fold induction relative to 
the reporter-only control and are the mean ± SD. (c) 293T cells were transfected with the 
IFNB reporter gene one day prior to stimulation. Cells were pre-incubated with live or UV 
(2J/cm2) inactivated HMPV-B1 (105pfu/ml) for 24 hours. Cells were then stimulated with 
HMPV-A1 (5x104pfu/ml) or NDV (8HAU) for an additional 24hours. Results are 
normalized by renilla luciferase and presented as fold induction relative to the reporter-
only control and are the mean ± SD. (d) 293T cells were transfected with the IFNβ 
PRDIII-I reporter gene and 40ng of plasmids encoding HMVB1 proteins as indicated. 
Cells were stimulated for an additional 24h with HMPV-A1 (5x104pfu/ml). Data were 
normalized by renilla luciferase and are expressed as a percentage of activation relative 
to conditions with the virus in the absence of exogenous proteins and are the mean ± 
SD. Protein expression levels were analyzed by WB. 
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viral genome of HMPV-B1 virus can be sensed by RIG-I, if delivered to the 
cytosol. However, the inability of the B1 strain to be sensed suggested that in the 
context of the virus, the HMPV-B1 viral RNA is not detected. There might be 
some proteins prevent the access of RIG-I.  
To test this hypothesis, we first tested if preincubation with the HMPV-B1 
strain could interfere with signaling initiated by the HMPV-A1 strain or other 
viruses that are sensed by RIG-I. Cells were transfected with the IFNB reporter 
gene, pre-incubated for 24 hours with live or UV-inactivated HMPV-B1 strain 
before infection with the A1 strain or NDV. Luciferase activity was then monitored 
24 hours post infection. Preincubation with live HMPV-B1 reduced IFNβ induction 
upon HMPV-A1 infection (Figure 3.3c). In contrast, preincubation with UV-
inactivated virus did not block the induction of IFNβ. The activation of the IFNβ 
reporter gene in response to NDV was not affected. These data suggest that the 
B1 virus interferes with the induction of IFNβ reporter by A1 virus and that the 
inhibitory effect was not due to antagonism downstream of RIG-I itself. Therefore, 
the B1 strain likely blocks sensing of HMPV viral RNA and not RIG-I function per 
se.  
Each individual cDNA from the B1 strain (with the exception of the L 
polymerase) were cloned into mammalian expression vectors and their effects on 
type I IFN induction upon infection with the A1 strain examined by reporter assay. 
Plasmids encoding B1 cDNAs were transfected into 293T cells together with the 
PRDIII-I reporter gene, whose activity was monitored after infection of cells with 
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HMPV-A1 virus. Table 3.1 shows the percentage identity between A1 and B1 
proteins. While the M, SH, M2-1, N, M2-2, F and G proteins had little or no effect, 
the P protein blocked the induction of the reporter (Figure 3.3d). Importantly, 
western blotting revealed good expression levels of all of these proteins in 
transfected cells.  
We next generated HEK293 cell lines stably expressing the B1-virus P 
protein in order to test if the B1 protein could prevent induction of IFNβ upon 
delivery of viral RNA into the cytoplasm. Viral RNA from both A1 and B1 strains 
triggered a strong IFNβ response in parental HEK293 cells but the response was 
largely impaired in HEK293 cells expressing B1-P protein. Importantly, IFNβ 
induced by vRNA from NDV or VSV was unaffected (Figure 3.4a). These data 
are consistent with the possibility that the HMVP-B1 P protein functions in a 
specific manner as an inhibitor, blocking IFN production in response to HMPV 
viral RNA.  
To further examine the inhibitory effect of the B1 virus P protein in a more 
physiologically relevant manner and in the context of the virus, we generated 
chimeric viruses in which the P protein from the A1-strain was replaced with that 
of the B1 strain. Both WT and chimeric HMPV-A1 virus were recovered from 
cDNA and their ability to induce type I IFN examined by reporter assays. 
Consistent with our data with the A1 clinical isolate, WT HMPV-A1 virus 
recovered from cDNA (referred to as A1R) induced IFNβ reporter in HEK293 
cells, however when A1 virus expressing the P protein from B1 virus (APB) was
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Table 3.1 Percent identity between HMPV-A1 and HMPV-B1 proteins  
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Figure 3.4 HMPV-B1 P protein prevents RIG-I from sensing HMPV vRNA. (a) 
HEK293 cells and HEK293 cells stably expressing the P protein from HMPV-B1 were 
transfected with the full length IFNβ reporter gene along with the viral RNA (80ng) 
purified from HMPV-A1, B1, NDV, or VSV, or with total RNA (80ng) purified from Vero 
cells as control. Results are normalized by renilla and pGL3 control luciferase, and 
presented as mean ± SD. (b-f) 293T and A549 cells were transfected with the full length 
IFNB or the PRDIV reporter along with the TK-renilla reporter gene, one day prior to 
stimulation. Cells were infected for 24 hours with the following viruses: HMPV-A1, 
HMPV-B1, A1R, or the chimeric virus APB (5x104pfu/ml). Results are normalized by 
renilla luciferase and are presented as fold induction relative to the reporter-only control 
and are the mean ± SD. A western blot of F protein levels is shown (f). (g) 293T cells 
were transfected with the IFNβ reporter gene and plasmids encoding HMVB1 P 
protein(5-40ng). Cells were stimulated for an additional 24h with PolyIC (200ug/ml) or 
HMPV-A1 (5x104pfu/ml). Results are normalized by renilla luciferase, and presented as 
mean ± SD. 
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examined, no reporter gene activity was detected (Figure 3.4b). Similar data 
were obtained when A549 cells were examined (Figure 3.4c). Since both the A1 
and B1 strains could induce PRDII and PRDIV-luciferase reporters, we also 
compared the effect of A1R and APB viruses on induction of these reporters in 
both HEK293 and A549 cells. In contrast to the IFNβ reporter, both A1R and APB 
induced both of these reporter genes in 293T cells (Figure 3.4d) and A549 cells 
(Figure 3.4e). Moreover, analysis of F-protein levels in virus infected cells 
revealed similar levels in cells infected with all viral strains (Figure 3.4f). These 
results provide compelling evidence that the HMPV B1-P protein prevents RIG-I 
mediated sensing and signaling resulting in IRF3–dependent type I IFN gene 
transcription. 
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 Discussion 
HMPV is a major contributor to lower and upper respiratory tract infections 
in infants and young children. Acute viral infections activate type I IFN antiviral 
responses that are essential for viral clearance. HMPV belongs to the 
paramyxovirus family that employs a variety of non-structural proteins including 
the alternative products of P gene and proteins encoded by NS genes to 
circumvent the IFN response thus to make the better environment for viral 
replication and expansion. Although many reports have shown the function of 
these proteins to inhibit type I IFN signalling in different genus (221), it is still not 
clear how HMPV counteracts the production of type I IFN. In the previous 
chapter, we demonstrated that type I IFN was induced during infection with 
HMPV viruses. HMPVA1 and B1 strains have the abilities to induce similar level 
of type I IFN in PDCs through endosomal TLR7. Sensing of HMPVA1 virus 
occurs via the cytosolic RNA helicase RIG-I in most cell types tested including 
human cell lines and purified human monocytes. We have also identified 5’- 
triphosphate RNA as the HMPV viral ligand triggering the RIG-I/type I IFN 
response. In these cell types, HMPVB1 failed to elicit type I IFN production.  
The major focus of this chapter was to understand the mechanism 
underlying the inability of HMPVB1 virus to trigger type I IFN production by 
comparing the innate response to two closely related strains. Despite its ability to 
infect and replicate as efficiently as the A1 virus and despite the ability of naked 
viral RNA to trigger RIG-I if delivered by lipofection to the cytoplasm, the live 
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HMPVB1 virus failed to activate RIG-I as HMPVA1 can do. The fact that the B1 
virus could prevent type I IFN induction by the A1 virus, but not that induced by 
NDV indicates that RIG-I signalling per se is not blocked by the B1 virus. Like the 
A1 virus, purified B1 viral RNA could trigger IFN and pretreatment of the B1 viral 
RNA with RNAse or removal of phosphate groups with alkaline phosphatase 
ablated sensing of the viral RNA by RIG-I. These studies suggest that RNA of 
both strains are ligands for RIG-I, however, in the context of the virus, the B1 
viral RNA is prevented from being sensed by RIG-I. During viral infection, RNA 
viruses like HMPV fuse with the cell membrane and deliver their 
ribonucleoprotein (RNP) complex into cells. The RNP complex consists of the 
viral RNA associated with the viral polymerase L, the nucleoprotein N and the 
phosphoprotein P. Upon fusion, the viral RNA is protected from free cellular 
RNases by this protein complex. Proteins within the RNP therefore could prevent 
the recognition of the vRNA by the RIG-I pathway. In fact, our studies using 
overexpressed B1 proteins indicated that the B1 virus P protein but not other 
HMPV proteins could block IFN production by live A1 virus or viral RNA. 
Although this approach indicated that the B1 P protein was the most likely 
candidate, we found that if we overexpressed the A1 P protein we could also 
observe an inhibitory effect. To determine if the B1 P protein was responsible for 
the inhibitory effect in the context of the virus, we generated recombinant viruses, 
where we replaced the P protein in the A1 virus with that from the B1 virus. This 
is a more physiologically relevant system to assess its contribution where 
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associations of the B-1 P with other viral proteins could also be accounted for. A 
recombinant A1 virus encoding the P protein from the B1 strain was generated 
and its ability to induce RIG-I signalling examined. Unlike the WT virus recovered 
from cDNA, the recombinant A1 virus containing the B virus P protein had a 
substantially reduced ability to induce IFN, suggesting that in the context of the 
entire virus, B1-P may indeed prevent RIG-I from sensing HMPV virus. Specific 
inhibition of RIG-I sensing by the B1-P protein could be because of higher levels 
of expression of the P protein in the B1 virus rather than what is found in the A1 
virus. Another possibility is that the B-1 P protein could have higher affinity for the 
RNA or for other components of the RNP complex (HMPV RNA or N and L), 
which would preclude the RNA from being sensed. The two P proteins share 
86% identity (see table 3.1) and therefore unique residues in B1-P could account 
for these effects. The inhibitory effect of the B1 virus P protein was restricted to 
the RIG-I pathway, since the B1 virus did not prevent induction of IFNB reporter 
gene activity by PolyIC/TLR3 signaling (Figure 3.4g). 
Usurping IFN induction pathways is a common tactic employed by viruses 
to enable their replication within host cells. Viral IFN antagonists strike at just 
about every level of the IFN regulatory network, but by far the best-studied 
strategies relate to the ability of viral proteins to counteract RNA sensing and 
signaling events. Examples include Influenza virus NS1, which inactivates RIG-I 
(199), HCV, NS3/4A, which cleaves and inactivates MAVS (86) and the 
phosphoprotein of Borna disease virus and Rabies virus, which target the IRF3 
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kinase, TBK1 (222, 223). In the case of RSV, the genome encodes two NS1 and 
NS2 proteins known to inactivate the IFN response (176). A recent study from 
Casola and colleagues implicated the G protein from another strain of HMPV in 
evasion of the RIG-I signaling pathway (224). A recombinant hMPV lacking the G 
protein (rhMPV-ΔG) was developed as a potential vaccine candidate and shown 
to be attenuated in the respiratory tract of a rodent model of infection. Casola and 
colleagues found that rhMPV-ΔG-infected airway epithelial cells produced higher 
levels of chemokines and type I interferon compared to cells infected with 
rhMPV-WT. They showed that RIG-I was the target of G protein inhibitory 
activity. Indeed the G protein associated with RIG-I and inhibited RIG-I-
dependent gene transcription. Our overexpression data with the HMPV-B1 virus 
however do not support a role for the B1-virus G protein but rather indicate that 
the B1 phosphoprotein can prevent RIG-I from sensing the viral RNA. However, 
we had problems to recover the recombinant B1 virus encoding P protein from 
A1 strain, it is possible that there’s other protein in the B1 virus contributing to the 
antagonism. 
Altogether, our data unveil a new strategy of HMPV virus to interfere with 
host innate defence. We proposed a model showing how these two HMPV 
strains are differentially sensed and how HMPV-B1 strain counteracts the 
recognition by RIG-I (Figure 3.5). A better understanding of the interactions 
between viral proteins and host innate immune defences is critical to improving 
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the knowledge about the pathogenesis of viruses, which will contribute to the 
development of better approaches for treatment and vaccines. 
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Figure 3.5 Schematic model of differential recognition of HMPV-A1 and B1 strains. 
In most cell types tested including human cell lines and isolated human monocytes, only 
HMPVA1 virus, but not B1 virus induces type I IFN production. The response is 
mediated by the cytosolic receptor RIG-I and its adaptor molecule MAVS. Purified viral 
RNA from both A1 and B1 viruses can be recognized by RIG-I. The HMPVB1 virus 
encodes an antagonist, P protein, which can prevent the recognition of B1 viral RNA by 
RIG-I. This ability to block vRNA recognition is unique to HMPV viruses as the B1 P 
protein does not appear to prevent RIG-I from sensing other viral RNAs. In contrast, we 
noted that in PDCs, there is no blocking of viral recognition, since TLRs control the 
induction of type I IFNs in response to both HMPVA1 and B1 viruses. These responses 
in PDCs do not involve RIG-I/MAVS pathway but instead involves sensing by endosomal 
Toll-like receptor 7.  
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Material and methods 
Cell lines.  
HEK 293, 293T, alveolar epithelial cells (A549) and Vero cells were from 
ATCC (Manassas, VA). The human hepatocellular carcinoma cell lines Huh7 was 
from C. Rice (Rockefeller University, New York, NY). HEK293 cells stably 
expressing the P protein from HMPV-A1 and B1 were generated by transfection 
with cDNAs encoding P proteins, which were generated by PCR. All of the above 
cell lines were maintained in DMEM (Mediatech Inc, Herndon VA) supplemented 
with 5% FBS (Hyclone, Logan UT) and 10mg/ml Ciprofloxacin (Mediatech Inc). 
BSR-T7/5 cells were from K. Conzelmann (Munich, Germany) and were cultured 
in DMEM 10%FCS/ciprofloxacin with G418 (0,5mg/ml).  
Reagents 
The trypsin-independent HMPV viral isolates A1 (NL\1\001) and B1 
(NL\1\99) were provided by Medimmune Inc. (Gaithersburg, MD) and were 
propagated as previously described in IMDM 4% BSA trypsin (206, 209). 
Newcastle disease virus (NDV, LaSota strain) was from P. Pitha (Johns Hopkins, 
Baltimore, MD). HMPV B1 was inactivated by UV cross-linking at a dose of 2 
Joules/cm2. Poly (dA-dT)•Poly (dA-dT) was from GE Healthcare (Piscataway NJ). 
The monoclonal antibodies specific for the HMPV F protein were generated and 
characterized by Medimmune Inc. (Gaithersburg, MD) (209). Biotinylated 
hamster monoclonal antibody #1017 was used at 1mg/ml for staining of the F 
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protein by immunoblotting and flow cytometry. Anti β-actin was from Sigma-
Aldrich (St. Louis, MI).  
Plasmids 
The IFNβ luciferase, pGL3-PRDII, -PRDIII-I and -PRDIV luciferase 
reporter genes were from T. Maniatis (Harvard, Cambridge, MA). ISG54-IFN-
stimulated regulatory element (ISRE) was from Stratagene (La Jolla, CA). Human 
RIG-IC (helicase domain only) were from T. Fujita (Tokyo, Japan). pGL4-TK 
renilla luciferase and pGL3-control luciferase were from Promega (Madison, WI). 
All viral proteins (with the exception of L) from HMPV-B1 were cloned individually 
into pEF-Bos-Flag by PCR using full-length cDNA as template (225). Clone 
sequences were verified by sequencing and protein expression in 293T cells by 
western blotting with anti-Flag M2 (Sigma-Aldrich, St. Louis, MI).  
Human primary cell isolation 
Peripheral blood mononuclear cells (PBMC) were freshly isolated by 
density-gradient centrifugation using Ficoll Hypaque (GE Healthcare). Monocytes 
and PDC were purified from PBMC using CD14 microbeads and the diamond 
PDC isolation kit respectively as recommended by the manufacturer (Miltenyi 
Biotec). Purity of these populations was assessed by staining for CD14 and 
BDCA2 expression by flow cytometry, and was greater than 95%.  
Reporter assays  
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Luciferase reporter assays were conducted as previously described (95). 
Briefly, 293T cells or A549 cells (2.104 cells/well in 96-well plates) or Huh7 cells 
(4.104 cells/well in 96-well plates) were transfected with the indicated luciferase 
reporter genes together with thymidine kinase Renilla-luciferase reporter gene 
and with of the indicated expression plasmids using Genejuice (Novagen, 
Madison, WI). Luciferase activity was measured as previously described (210).  
Viral RNA Purification 
Viral RNA from HMPV-A1 and B1 was extracted using the QIAamp viral 
RNA mini kit (Qiagen, Valencia, CA). Viruses were concentrated by 
ultracentrifugation for 2h at 4 °C at a speed of 27,000 RPM using a SW28 rotor 
(Beckman, CA). RNA (1.5mg) was treated with or without 10U of calf intestinal 
alkaline phosphatase (CIAP, Fermentas) for 3h at 37°C or RNase A (Promega) 
for 1h at 37°C. All samples were then treated for 15min at 85°C to inactivate the 
enzymes. Viral RNA was transfected into 293T cells using lipofectamine 2000 at 
a ratio 1:1 (weight/volume) along with the IFNβ luciferase and the TK-renilla 
reporter genes according to the manufacturer instructions (Invitrogen). Viral RNA 
from NDV and VSV were from T. Morrison and S. Zhou, respectively (UMASS 
Medical School, Worcester, MA). 
RNA extraction and real time PCR 
293T cells (2.106cells per 10 cm plate) were stimulated with HMPV-A1 or 
HMPV-B1 (3.2.105pfu/ml) for 5 to 48h and RNA isolated using RNeasy (Qiagen, 
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Valencia CA). cDNA were synthesized as previously described (95) using the 
SuperScript III enzyme (Invitrogen). Quantitative real-time PCR analysis was 
performed using SYBR green reagent (Invitrogen) on a DNA engine Opticon 2 
cycler (Bio-Rad, Hercules CA) using the following primers: β−actin-F 
CCTGGCACCCAGCACAAT; β−actin-R GCCGATCCACACGGAGTA; L1-F 
TTGCATGAGGTACCTTGGATTG; L1-R AGAGTGCATTATCACACATCA. The 
specificity of amplification was assessed for each sample by melting curve 
analysis, and the size of the amplicon checked by electrophoresis. PCR 
efficiency was calculated for both vRNA with ten-fold dilutions of the cDNA with 
the formula E = 10[–1/slope]-1 as previously described (213). Relative quantification 
was performed using standard curve analysis. All gene expression data were 
normalized with β-actin and are presented as a ratio of gene copy number per 
100 copies of β -actin +/-SD. 
Western-Blotting  
Whole cell extracts were prepared using lysis buffer (50 mM Tris (pH 7.5), 
150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 10% glycerol, freshly 
supplemented with protease and phosphatase inhibitors. Cells were placed on 
ice for 15min and centrifuged for 15min at 14,000rpm. 30mg of protein were 
analyzed by 10% SDS-PAGE and subjected to immunoblot analysis using anti-F 
and anti-β-actin antibodies as indicated. The IRF3 dimerization assay was 
performed as follows. A549 cells (10.106cells /10ml in 10cm plate) were 
stimulated with HMPV-A1, B1 (10^5 pfu/ml) or NDV (40 HAU) as indicated. 
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Nuclear proteins were extracted using Nuclear Extraction Kit (Active Motif, CA). 
25 µg of protein was analyzed by 8.5% PAGE and subjected to immunoblot 
analysis using anti-IRF3.   
Generation of chimeric viruses 
Chimeric viruses where the P proteins both HMPV strains were 
exchanged, were generated by PCR using naturally occurring MluI and PacI 
enzymes and Esp31 enzyme to generate overlapping PCR fragments. PCR 
fragments were generated using full length cDNA as previously described (225). 
For each virus strain, 3 PCR products were generated and cloned in topo cloning 
vector (Invitrogen). From the MluI site to the ATG of the P protein, the P protein 
and to the end of P up to PacI site. Ligations of MluI to P and P to PacI from each 
strain were ligated with the P protein from the opposite virus strain into pCDNA3. 
HMPV-A1 and B1 full length was generated by partial digestion using MluI and 
PacI and used to clone the 3 pieces by PCR from pCDNA3. Colonies were 
screened by digestion and sequenced by PCR.  
Virus recovery and titration 
Recovery of recombinant HMPV was performed as described previously 
(225). Briefly, BSR-T7 cells were transfected with 5 µg full-length HMPV cDNA 
plasmid, 2 µg pCITE-N, 2 µg pCITE-P, 1 µg pCITE-L and 1 µg pCITE-M2.1 using 
Genejuice (Novagen). Two days later, the BSR-T7 cells were scraped and co-
cultured with Vero cells in IMDM with 4% BSA for 7 days.  Viruses were titered 
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as followed. Twenty-four-well plates containing 95% confluent monolayers of 
Vero cells were inoculated with 200µl of 10-fold serial virus dilutions. After 2 h at 
37 °C, 0.8ml of 0.5% methylcellulose/DMEM with 3% FCS was added. Cells 
were incubated for an additional 5 days. Methylcellulose overlays were removed 
and cells were fixed with 80% acetone. Cells were incubated with HMPV-specific 
1017 biotinylated antibody (Medimmune) for 1 h at 37 °C, followed by incubation 
with horseradish peroxidase-labelled streptavidin (BD bioscience, CA). Plaques 
were quantified after incubation with a freshly prepared solution of 3,3' 
Diaminobenzidine (DAB) (Vector Laboratories, CA) to determine viral titers. 
Statistical analysis 
Differences between groups were analyzed for statistical significance by 
using a t-test in Prism software. P<0.05 was considered statistically significant. 
***,  ** and * represent p values of <0.001, <0.01 and <0.05, respectively. 
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Chapter IV IRF5 function in innate immune response 
 
Abstract 
IRFs are key regulators of innate immune signaling and were first 
implicated as critical transducers of type I IFN responses. IRF3 and IRF7 have 
been best studied and their role in IFN gene regulation in TLR, RLR and cytosolic 
DNA sensing pathways is now clear. In contrast, although IRF5 has also been 
implicated in anti-viral defenses, its precise role is much less clear. In particular 
very little was known about murine IRF-5. Murine IRF-5, unlike the heavily 
spliced human gene, is expressed as a full-length transcript, with only a single 
splice variant. The murine IRF-5 protein can be activated downstream of MyD88 
to form homodimers and bind to and activate transcription of type I interferon and 
inflammatory cytokine genes. In this chapter, by examining immune responses in 
IRF5-deficient mice, we found that IRF5 contributes to various aspects of TLR 
signaling. These studies revealed that IRF-5 was critical for TLR3-, TLR4-, and 
TLR9-dependent induction of TNFα in CD11c+CDCs from mouse spleen. In 
addition, TLR9, but not TLR3/4-mediated induction of type I IFN transcription, 
was dependent on IRF-5 in these cells. In addition, these studies also found that 
the role of IRF5 in these responses was restricted to splenic cells, no role for 
IRF5 was found in macrophages or DCs generated from bone marrow. 
We also contributed to the discovery of a new mechanism that triggered 
IRF5. Stimulation of NOD2-RIP2-IRF5 signaling pathway by MDP components 
from Mtb induced type I IFN production.  This study identified a new role for IRF5 
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besides its known function in MyD88 dependent TLR7/9 signaling pathways.  
These data reveal the cell type-specific importance of IRF-5 in MyD88-mediated 
antiviral pathways as well as RIP2-dependent anti-bacterial responses and the 
widespread role of IRF-5 in the regulation of inflammatory cytokines. 
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Introduction 
The IRF family has been reported to have multiple functions in the 
immune system. These include regulation of immune cell development and 
transcription of type I Interferon genes. The search for transcription factors 
activating the promoters of IFNA and IFNB genes led to the identification of IRF-3 
and IRF-7. Another member of the IRF family, IRF-5, was then identified and also 
implicated in innate immunity. HuIRF-5 is expressed primarily in DCs and B cells 
and shows some properties that are different from IRF-3 and IRF-7. Unlike IRF-3 
and -7, IRF5 contains two nuclear localization signals, and consequently low 
levels of nuclear IRF-5 can be detected in the nucleus of uninfected cells (226). 
Human IRF-5 is expressed in multiple spliced variants, and some of these are 
transcriptionally inactive and may function as dominant negative mutants (227). 
HuIRF-5 was shown to regulate IFN gene expression in response to some 
viruses and TLR ligands. A role for IRF-5 in IFNα synthesis has also come from 
genetic studies of SLE, which is characterized by a constitutive expression of 
IFNα/β. Variants of IRF-5 have now been linked to SLE (228), as well as 
inflammatory bowel disease (229). 
In vitro experiments have shown that in infected cells, HuIRF-5, like IRF-3 
and IRF-7, is activated by phosphorylation, resulting in nuclear translocation and 
stimulation of IFNA gene expression (230). Studies from the Pitha lab have 
shown that IRF-5 specifically up-regulates early inflammatory cytokines and 
chemokines in addition to IFNα (226). While the TLR3-TRIF pathway activates 
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both IRF-3 and IRF-7 via TBK-1, these mediators do not appear to regulate IRF5. 
In contrast, IRF-5 is activated by MyD88-dependent pathways through a TRAF6- 
and IRAK1-dependent mechanism (125). Initial analysis of the role of IRF-5 in 
the innate antiviral response in Irf5–/– mice showed impairment in the TLR9-
mediated induction of IL-6 and TNFα in CDC. However, unlike PDCs from Irf7–/– 
mice, which are severely compromised in CpG-DNA-induced IFN responses, 
PDCs from Irf5–/– mice did not show any defect in the induction of IFNα (128). 
The impairment of TNFα, IL-6, and IL-12p40 was not limited to TLR9-mediated 
induction but was also observed in the TLR4 and TLR3 responses of splenic 
macrophages; however, the induction of type I IFN in Irf5–/– cells in response to 
these inducers was not examined (128). Recent observations have shown that 
IRF-5 plays a role in IFNα induction by RNA-containing immune complexes 
present in the sera of SLE patients (231). Yasuda et al. stimulated a mixture of 
CDC and PDC derived from the bone marrow of C57BL/6J and Irf5–/– mice with 
IgG from lupus sera, the TLR9 ligand CpG-A, or the TLR7 ligand R848 and 
showed that production of IFNα and IL-6 was largely abolished in Irf5–/– cells, a 
result that is in contrast to the report by Takaoka et al. (128). 
To clarify the apparent contradictions between the roles of HuIRF-5 in the 
antiviral response (in particular the type I IFN response) in vitro and MuIRF-5 in 
vivo, the work described in this chapter determined the functional properties of 
MuIRF-5 in vitro. These studies revealed that IRF-5 plays an important role for 
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IFNα induction in CD11c+CDCs from mouse spleen and also revealed the 
important role of IRF5 in regulation of TNFα downstream of multiple TLRs.  
In addition to examining the role of IRF5 in TLR signaling, we also 
examined the role of IRF5 in additional pathways important in innate immunity. 
These studies led to the finding that RIP2, which functions in NOD signaling can 
also act as an upstream mediator of IRF5 signaling. RIP2 plays a critical role in 
activating the signaling pathways downstream of the NOD1/2, which recognize 
bacterial PGN fragments (232). NOD1 and NOD2 belong to the NLR family. In 
contrast to TLRs which recognize microbial components at the cell surface or 
inside endosomes, NLRs are cytosolic receptors specialized in bacterial 
recognition. In response to Lm infection, activated NOD1 and NOD2 recruit RIP2 
for downstream signaling and proinflammatory cytokine production (232). RIP2 is 
a serine-threonine kinase that belongs to the same family as RIP1, a mediator of 
TLR signaling. Overexpression of RIP2 stimulates NFκB activity and induces 
apoptosis (233). In RIP2 deficient MEFs, NOD1 and NOD2 cannot activate NFκB 
signaling, suggesting a critical role of RIP2 in NOD1/2 pathway (234). NOD2 has 
also been shown to be involved in type I IFN production upon intracellular 
bacteria infection since the induction of IFNβ was reduced in NOD2 deficient 
macrophages during infection with either Lm or Mtb (235). In this chapter, we 
investigated the function of IRF5 in the NOD2-RIP2 pathway. Our data revealed 
that IRF5 could be activated by RIP2. Furthermore, this led to studies in 
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collaboration with the Kelliher and Sasetti laboratories, which showed that IRF5 
was involved in Mtb induced IFNβ production. Mtb infection activates more than 
one signaling pathway for type I IFN expression. Live Mtb induced IFNβ is TBK1 
dependent and dependent on both IRF3 and 5.  N-glycolyl MDP could also turn 
on IFNB gene expression via NOD2-RIP2-IRF5 and did not involve IRF3. This is 
the first work to implicate IRFs in signaling downstream of NLRs and the first to 
reveal the important role of IRF5 in response to bacterial infection.  
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Results 
IRF5 plays important role in antiviral and anti-inflammatory function in vivo.  
Previous data in our lab had shown that IRF5 was involved in TLR7/9 
signaling for induction of type I IFN in a MyD88 dependent manner (125). Initial 
analysis of the role of IRF-5 in the innate antiviral response in Irf5–/– mice showed 
that induction of IL-6 and TNFα in splenic DC following CpG DNA treatment was 
severely compromised in IRF5-deficient mice. Surprisingly, PDCs from Irf5–/– 
mice produced normal levels of IFNα (128). TNFα, IL-6, and IL-12p40 were also 
decreased in response to ligands for TLR4 and TLR3; however, the induction of 
type I IFN in Irf5–/– cells in response to these inducers was not examined. We 
therefore wanted to perform a more detailed study to examine the role of IRF5 in 
antiviral and anti-inflammatory response and especially in type I IFN production.  
We generated mouse BMDC and stimulated them with ligands for TLR2 
(Pam2Cysk4), TLR3 (polyIC), TLR4 (LPS), TLR7/8 (R848), TLR9 (CpG-B) and 
viruses. Mouse TNFα and IFNβ levels were quantified in the supernatant by 
ELISA. No difference in TNFα level was observed between WT and IRF5 
deficient BMDC (Figure 4.1a). While Pam2Cysk4, R848 and CpG-B didn’t induce 
detectable IFNβ, LPS, PolyIC and viruses (SV, NDV) induced comparable 
amounts of IFNβ in WT and IRF5 BMDCs (Figure 4.1b). We also generated 
mouse BMDM, stimulated them with TLR3, TLR4, and TLR9 ligands, and 
monitored IFNβ RNA level by real-time PCR. We observed similar IFNβ levels in
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Figure 4.1 IRF5 is not involved in the IFNβ  production in BMDC or BMDM (a-b) 
mouse BMDCs (2.105/well) were stimulated with CpG-B (2uM), polyIC (20ug/ml), LPS 
(20ng/ml), pam2 (10nM), R848 (10nM), SV (40HAU), or NDV (16HAU) for 24hrs. Protein 
levels were measured in the supernatant of culture by ELISA and presented as the 
mean ± SD. (c) mouse BMDMs (2.105/well) were stimulated with CpG-B (2uM), polyIC 
(20ug/ml), or LPS (20ng/ml) for 6hrs. Levels of murine IFNβ and β-actin were quantified 
in RNA samples by real-time PCR. Results are presented in arbitrary units as the ratio of 
IFNβ over 100 copies of β-actin. 
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WT and IRF5 deficient BMDM upon polyIC and LPS stimulation (Figure 4.1c). 
These data indicated that IRF5 dose not play a role in type I IFN production in 
response to most TLR ligands in BMDM and BMDC. Moreover, type I IFN 
production in response to SV and NDV, that mainly signal through RIG-I and 
MDA-5 in these cell types, was also not dependent on IRF5. 
To further examine the role of IRF5 in other cell types, total splenic DCs (panDC) 
were purified using a mix of CD11c+ and mPDCA1+ beads (to assure isolation of 
all DC types from spleen including CDC and PDC) and CD11c+CDC were 
purified using CD11c+ beads from WT and IRF5 deficient mouse spleen, and 
stimulated with TLR3, TLR4, TLR9 ligands and NDV. Similarly to previously 
published data, IRF5 deficient splenic panDC and CD11c+CDCs displayed 
impaired TNFα levels in response to TLR3, TLR4 and TLR9 ligands (Figure 4.2a, 
b). In contrast to the BMDC and BMDM where no effect of IRF5 deficiency was 
observed, the splenic panDC population from IRF5 deficient mouse showed a 
significant decrease in the induction of IFNβ in response to CpG-B DNA.  A 
partial defect in response to TLR3 and NDV was also revealed, while the TLR4 
ligand only induced very low levels of IFNβ even in WT cells (Fig 4.2c). 
CD11c+CDC isolated from mouse spleens contain low numbers of PDC, since 
mouse PDC express very low levels of the CD11c surface marker. We found that 
IFNβ RNA levels were comparable between WT and IRF5 deficient CD11c+CDC 
in response to TLR3 and TLR4 ligands, while they still displayed significantly 
impaired IFNβ RNA level in response to the TLR9 ligand, CpG-B (Figure 4.2d).
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Figure 4.2 IRF5 plays an important role in type I IFN production in CD11c+CDCs (a, 
c) splenic panDCs (2.105/well) were stimulated with CpG (2-0.2uM), polyIC (20-2ug/ml), 
LPS (20-2ng/ml), or NDV (16-1.6 HAU) for 24hrs. Protein levels were measured in the 
supernatant of culture by ELISA and presented as the mean ± SD. (b) Left panel, 
CD11c+CDCs (2.105/well) were stimulated with CpG (2-0.2uM), polyIC (20-2ug/ml), or 
LPS (20-2ng/ml) for 24hrs. Protein levels were measured in the supernatant of culture by 
ELISA and presented as the mean ± SD. (b) Right panel and (d), CD11c+CDCs 
(2.105/well) were stimulated with CpG-B (2uM), polyIC (20ug/ml), or LPS (20ng/ml) for 
6hrs. Levels of murine TNFα (b) or murine IFNβ (d)  and β-actin were quantified in RNA 
samples by real-time PCR. Results are presented in arbitrary units as the ratio of IFNβ 
over 100 copies of β-actin.  
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Comparing this results with that of panDC, this data implied that TLR9 ligands 
triggers IFNβ via IRF5 in contrast to other ligands in splenic CD11c+CDCs which 
most likely require IRF3 and/or IRF7. IRF5 did not appear to contribute to IFNβ 
production in response to LPS or polyIC in splenic CD11c+CDCs. These 
observations support the role of IRF5 as a downstream effector of MyD88 
signaling. A similar defect in IFNβ induction was also found when the splenic 
CD11c+CDC from IRF5 deficient mice were stimulated with the TLR7 ligand 
R848 (Dr. P. Pitha, unpublished observation). Collectively, these data support an 
important role for IRF5 in TLR7 and 9 signaling in some DC cell subsets.  
 
IRF5 can be activated by RIP2 and involved in Mycobacterium Tuberculosis 
(Mtb) induced IFNβ production. 
The data presented above support the involvement of IRF5 as a mediator 
of MyD88 dependent pathways that control IFNβ production. In an effort to 
search for other pathways in which IRF5 may play a role, we wanted to examine 
the role of IRF5 in signaling by other receptors. These studies initiated with an 
examination of the role of RIP1 and RIP2 kinases in IRF5 signaling.  RIP1 is a 
mediator of TNFR signaling (236-239) as well as signaling by TLR3 and 4 ligands 
(159, 240). RIP2 is a mediator of NOD 1 and NOD2 signaling (232). We thereby 
tested the activation of IRF5 by RIP2 using a reporter assay. To test the ability of 
these kinases to regulate IRF5 activation, we took advantage of a sensitive 
reporter assay, which we had previously used to examine the ability of MyD88 to 
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turn on IRF5 signaling. HEK293 cells were transfected with an IFNB reporter 
gene, either in the presence or absence of low concentrations of IRF5. These 
cells were then co-transfected with increasing concentrations of candidate 
activators including MyD88. At low concentrations, neither IRF5 nor MyD88 alone 
can induce IFNB reporter gene activity. However, in the presence of IRF5, 
MyD88 activates the IFNB reporter gene in a dose dependent manner. Using a 
similar approach we compared the effect of RIP2 to MyD88 in this assay. As 
seen in Figure 4.3a, similarly to MyD88, which can activate IRF5 to induce the 
IFNβ reporter, RIP2 was also a potent activator of IRF5 to induce IFNβ reporter. 
In contrast, IRF3, another IRF family member that is very critical for early type I 
IFN production downstream of multiple PRRs, did not appear to function 
downstream of RIP2 (Figure 4.3b). These results indicated that RIP2 can target 
the IRF5 pathway to trigger type I IFN production.  
As a member of the IRF family like IRF3 and IRF7, IRF-5 can be 
phosphorylated in vitro by TBK1 kinase as shown in in vitro kinase assay (125). 
Phosphorylated IRF5 translocates to the nucleus and promotes type I IFN 
expression (230). Like TBK1, RIP2 also contains an N-terminal Serine/Threonine 
kinase domain (233), however the role of its kinase activity in mediating the 
signaling in NOD1/2 pathway remains unclear. We thus wanted to test whether 
IRF5 can be phosphorylated by RIP2 via its kinase activity. We performed in vitro 
kinase assay using purified IRF5 protein C-terminal transactivation domain 
(residues 222-467) (241) and myelin basic protein (MBP) as substrates, and
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Figure 4.3 IRF5 can be activated by RIP2 for type I IFN production (a) HEK293T 
cells were co-transfected with IFNβ-luciferase reporter plasmid (40 ng) together with the 
indicated concentrations of MyD88, IRF5 and RIP2 expression plasmids. (b) HEK293T 
cells were co-transfected with IFNβ-luciferase reporter plasmid (40 ng) together with the 
indicated concentrations of IRF5, IRF3 and RIP2 expression plasmids. In both cases, 
Luciferase activity was measured 24 h later using Dual Luciferase reporter assay system 
(Promega). The Renilla luciferase gene (40 ng) was co-transfected and used as an 
internal control. Each experiment was repeated three times. Data are expressed as 
mean±s.d. of three replicates. (c) the reaction was prepared in 10µl of buffer A (20mM 
Hepes, pH7.6/20mM β -glycerophosphate/0.1mM sodium orthovanadate/10mM 
MgCl2/50mM NaCl/1mM DTT) containing 1µg of IRF5 or MBP protein substrate and 
10ng recombinant TBK1 protein or RIP2 protein, 50µM ATP, and 5µCi of [γ-32P]ATP (1Ci 
= 37GBq), and conducted at 30°C for 30 min. Reaction products were subjected to 
analysis in 10% SDS- PAGE gels. 
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purified TBK1 and RIP2 proteins as kinases. Unlike TBK1, which successfully 
phosphorylated IRF5, RIP2 failed to do so (Figure 4.3c).  In contrast, RIP2 
phosphorylated MBP strongly. These results revealed that RIP2 could not directly 
phosphorylate IRF5 and instead must activate IRF5 via other mechanisms. One 
possibility is that downstream of RIP2, other kinases, such as TBK1, might be 
recruited to activate IRF5 for type I IFN production.  
Mtb infection can induce rapid and robust type I IFN production, and our 
collaborators recently showed that NOD2 and RIP2 played a critical role in this 
signaling pathway (242). IRF3, but not IRF5, has been shown to be critical for 
type I infection in early response to bacteria infection, like Lm (243-246). Given 
the data above that Rip2 and IRF5 can synergistically induce high level of IFNβ 
in reporter assay, we tested whether IRF5 could be involved in the Mtb induced 
type I IFN production. We observed that Mtb-induced type I IFN expression was 
severely impaired in IRF5 deficient macrophages (Figure 4.4a) suggesting that 
IRF5 played an important role in type I IFN induction. As control, the response to 
Lm, which is totally dependent on IRF3 (244-246), was unaffected in the absence 
of IRF5 (Figure 4.4a). While the related RIP1 adaptor protein has been 
implicated in IRF7 activity in innate anti-viral signaling (247), IRF7 was not 
involved in this RIP2 pathway since IRF7 deficient macrophages did not display 
any difference in type I IFN production in response to Mtb infection compare to 
WT macrophages (Dr. M. Kelliher unpublished data). IRF3 seems to also play a 
partial role in type I IFN production in response to whole Mtb, since type I IFN
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Figure 4.4 IRF5 is involved in IFNβ  production induced by MTB (a) BMDM from 
irf5−/− or control littermates were infected with virulent Mtb H37Rv (Rv) at an MOI of 10, 
or with Listeria monocytogenes (Lm) strain 10403S (MOI 10) for 4 hours. (b) BMDM 
derived from wt and irf3−/− mice were infected with virulent Mtb H37Rv (Rv) at an MOI 
of 10 for 4 h. (c) BMDM derived from Irf3+/+Irf5+/+, Irf3-/-Irf5-/-, Tbk1+/+Tnfr1-/- and 
Tbk1-/-Tnfr1-/- mice were left uninfected (UI) or infected with virulent Mtb H37Rv (Rv) at 
an MOI of 10 for 4h. (d) BMDM derived from irf3−/− and irf5−/− mice and their littermate 
controls were left untreated or treated for 6 hours with 10 µg/ml of N-Glycolyl-MDP. In all 
cases, RNA was harvested, and IFNβ mRNA level was quantified using real time PCR. 
Gene expression is reported as copy number per 1,000 copies of β-actin. Samples were 
assayed in triplicate; error bars represent the standard deviation. The experiment shown 
is representative of at least three. 
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levels were reduced in IRF3 deficient macrophages compared to WT (Figure 
4.4b).  Furthermore, IFNβ activation is entirely dependant upon IRF3 and IRF5 
since IFNβ production was totally abrogated in IRF3/IRF5 double KO cells 
(Figure 4.4c). Since TBK1 can phosphorylate both IRF3 and IRF5, we also test 
its role in IFNβ induction upon Mtb infection. These results showed that IFNβ 
production was totally TBK1 dependent (Figure 4.4c).  
The data above showed that the IFNβ induction by the whole TB is TBK1 
and IRF3/IRF5 dependent. Since NOD2/RIP2 pathway was triggered by N-
glycolyl MDP produced by Mtb (242), we assessed the involvement of IRF5 and 
IRF3 in this MDP/NOD2/RIP2 pathway. Consistent with the luciferase reporter 
assay above showing that RIP2 can activate IRF5 but not IRF3 for type I IFN 
induction, the IFNβ production induced by N-glycolyl MDP was only dependent 
on IRF5, and was entirely independent of IRF3 (Figure 4.4d). These data 
indicated that Mtb activates more than one signaling pathway for type I IFN 
expression. On one hand the whole bacterium activates both IRF3 and IRF5 
pathways while the purified N-glycolyl form of MDP produced by Mtb rather 
triggers NOD2-RIP2-IRF5 pathway for type I IFN production. 
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Discussion 
In recent years, considerable progress has been made in our 
understanding of the mechanisms underlying the detection of viruses and other 
pathogens and the signaling pathways leading to the production of type I IFN 
genes, the key workhorses of the anti-viral response. IRF3 and IRF7 have been 
known for some time to play a major role in these responses and their role in 
host-defense to viruses is very clear. The importance of these IRFs is supported 
by the fact that mice lacking one or other of these IRFs are susceptible to virus 
induction. Much less was known about the related protein IRF5, which early 
studies implicated in the antiviral response. A key question that arose from the 
early studies on IRF5 was whether this factor really participated in the production 
of type I IFNs.  
In this chapter of this thesis, we attempted to clarify this issue. We took 
advantage of the recently generated mouse lacking IRF5.  Four different cell 
types were isolated and used to investigate the role of IRF5 in IFNβ as well as 
proinflammatory cytokine production in response to TLR ligands and viral 
stimulations. Our data revealed the unique involvement of IRF5 in the activation 
of IFNβ in response to TLR7 and TLR9 signaling (our own data and that of our 
collaborator, Dr. P. Pitha). This role for IRF5 was apparent in splenic 
CD11c+CDCs, but not in macrophages or DCs isolated from mouse bone 
marrow or in PDCs isolated from spleen. TLR7 and TLR9 signal through the 
adaptor protein MyD88 and recruit a protein complex containing IRAK4, IRFAK1, 
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TRAF6 and TRAF3. In PDCs, this pathway leads to phosphorylation and 
activation of IRF7, while in the cells above, this same pathway converges on 
IRF5. In support of this model, IKKα has been shown to regulate IFNB responses 
via IRF5 and IRF7.  Although IRF7 has clearly been shown to be phosphorylated 
by IKKα, it is less clear if IKKα is involved in IRF5 phosphorylation. In addition to 
phosphorylation, K63-linked ubiquitination has also been implicated in IRF5 
activation (248, 249). The activation of type I IFN by TLR3 and TLR4 is mediated 
through the adaptor protein TRIF, which recruits RIP1, TRAF6 and TRAF3 to 
activate TBK1/IKKε for IRF3 activation. Although IRF5 can be phosphorylated by 
overexpression of IKKε and TBK1 in vitro, the phosphorylation alone did not 
seem to result in IRF5 nuclear localization or activation (250). These two different 
pathways may explain the differential involvements of IRF5 in regulating the type 
I IFN production in CDCs versus other cell types. 
Our results with isolated IRF5 deficient splenic panDC also showed similar 
defects in IFNβ activation in response to TLR9 ligand CpG-B. The panDC 
population consists of two subtypes: CD11c+CDCs and PDCs. By comparing the 
results of CDC and panDC, we concluded that the decrease of IFNβ in response 
to TLR9 ligands in IRF5-deficient cells is due the deficiency of IRF5 in 
conventional DCs but not PDCs. These observations are consistent with those of 
Takaoka et. al. which showed that PDC responses to TLR ligands did not depend 
on IRF5. However, our data expand on these studies by revealing that in some 
DC subsets, TLR9 and TLR7 activate IRF5 for IFNα production. Thus, we 
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proposed a model of differential involvements of IRF7 and 5 for type I IFN 
production in splenic PDCs and CDCs (Figure 4.5).  
In addition to the role of IRF5 in IFN production, our data as well as those 
from Takaoka and colleagues also revealed a role for IRF5 beyond IFN gene 
regulation. TNFα production was also defective in IRF5 –deficient splenic DCs in 
response to ligands for several TLRs. This is consistent with the previous report 
showing the important role of IRF5 in the production of inflammatory cytokine, 
such as IL-6, TNFα, and IL-12 in splenic DCs and macrophages (128). In this 
report, the authors analyzed and identified the potential IRF5 binding site, ISRE, 
in the sequences of these genes, which support a model where IRF5 regulates 
these inflammatory cytokines via binding to the ISRE sites within the promoters 
of these genes. In a manner similar to IFNB enhancesome formation, a model 
could be proposed whereby IRF5 binding to ISRE sites, cooperates with NFκB 
bound to NFκB sites to coordinate transcription of inflammatory cytokines. 
Further studies are required however, to definitely prove that IRF5 cooperates 
with other transcription factors on the promoters of these inflammatory cytokines.  
A surprising finding from our studies was the lack of a phenotype in BMDCs and 
BMDMs from IRF5-KO mice. We found no difference in TLR driven TNFα or 
IFNβ production between WT and IRF5 deficient cells in response to TLR ligands 
and viral stimulation. We speculate the reason might be that BMDCs and 
BMDMs are derived from in vitro culture with high doses of cytokines, which 
could prime these cells during the culture procedure. Thus, the role of IRF5 in 
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Figure 4.5 Schematic model of differential involvement of IRF5 for type I IFN 
production in splenic PDCs and CDCs. In PDCs, TLR7/8 and TLR9 signal through the 
adaptor protein MyD88 and recruit a protein complex containing IRAK4, IRAK1, TRAF6 
and TRAF3. In splenic PDCs, this pathway leads to phosphorylation and activation of 
IRF7 through IKKα for type I IFN production. In the splenic CDCs, these same ligands 
trigger TLR-MyD88 signaling which does not appear to activate IRF7. Rather, this 
pathway involves IRF5, which is regulated by both phosphorylation and 
polyubiquitination. The activation of type I IFN by TLR3 and TLR4 in CDCs is mediated 
through the adaptor protein TRIF, which recruits TRAF3 to activate TBK1/IKKε and 
consequently IRF3 driven IFN responses.  
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these cells may be masked by these priming cytokines, which might elevate 
expression of IRF7 to compensate for a lack of IRF5. 
Besides viruses, bacterial pathogens also trigger type I IFN responses and 
the mechanisms underlying this response are only beginning to be elucidated. 
Recent reports indicated that Lm infection or transfection of DNA into the cytosol 
induce IFNβ response via TBK1 and IRF3.  RIP-2 does not play a role in this 
cytosolic DNA driven IFNB response (244). Our data with RIP2 and IRF5, 
suggests an additional mechanism by which bacteria can elicit IFNB responses. 
Moreover, the Mtb studies, reveal that bacterial PAMPs, such as MDP, can 
synergize with the cytosolic DNA response in order to elicit maximal IFN 
production (235). In this study, we revealed that MDP generated during Mtb 
infection can activate NOD2-RIP2-IRF5 signaling and is sufficient to induce type I 
IFN production. This model therefore expands our understanding of IRF5 
function by revealing that in addition to its function in Myd88 dependent TLR7/9 
signaling, IRF5 is also a transducer of NOD signaling. When infected with whole 
Mtb, IFNβ production is impaired but still a significant part is remaining in IRF5 
deficient macrophages comparing to WT, indicating that additional pathways 
exist besides the MDP-NOD2-RIP2-IRF5 pathway.  The failure of Mtb to drive 
IFNβ in IRF3/IRF5 double KO cells supports a model where two distinct 
pathways cooperate for maximal responses. Understanding the molecular basis 
for IFN response to pathogens such as Mtb is important as it reveals potential 
targets to manipulate this response in situations where IRF signaling is beneficial 
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to host survival. For example, vaccines could be improved by including agents 
that activate IRF3 as well as IRF5. In contrast, where IRF activation is harmful to 
the host, such as in autoimmune diseases like SLE, inactivating the IRF5 
pathway could have important consequences for the treatment of this debilitating 
disease.  
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Material and methods 
Cells and mice 
HEK 293T, L929 cells were from ATCC (Manassas, VA) and were 
maintained in DMEM (Mediatech Inc, Herndon VA) supplemented with 5% FBS 
(Hyclone, Logan UT) and 10mg/ml Ciprofloxacin (Mediatech Inc). C57/Bl6 and 
C57/BL6-129 F1 mice were from Jackson Laboratories (Bar Harbor, ME). Irf5–/– 
mice was generously provided by Dr. T. Mak (University of Toronto, Canada). 
Tbk1-/+ mice were a gift from W.C. Yeh (University of Toronto, Canada) and 
were bred with Tnfr1-/- mice at the University of Massachusetts Medical School 
until TBK1-/-TNFR1–/– mice were achieved. Animal studies have been reviewed 
and approved by the University of Massachusetts Medical School institutional 
animal care and use committee. 
Plasmids and Reagents 
The IFNβ luciferase reporter gene was from T. Maniatis (Harvard, 
Cambridge, MA). Full length IRF5-Flag, huIRF3-Flag, and MyD88-HA were from 
P. Pitha (Johns Hopkins, Baltimore, MD). pCI-RIP2 was from Millennium 
Pharmaceuticals, Inc (San Diego, CA) . pGL4-TK renilla luciferase and pGL3-
control luciferase were from Promega (Madison, WI).  
Newcastle disease virus (NDV, LaSota strain) was from P. Pitha (Johns 
Hopkins, Baltimore, MD). Sendai virus was from Charles River Laboratories 
(Boston, MA). 
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The WT M. tuberculosis H37Rv strain was cultured in 7H9 medium 
containing 0.05% Tween 80 and OADC enrichment (Becton Dickinson). Bacterial 
clumps were removed by passing the washed suspension through a 5 µm 
syringe filter before infection. Pre-titered stocks of Listeria monocytogenes strain 
10403 stored at −80°C (kindly provided by Victor Boyartchuk) were recovered for 
1 hr at 37°C in 9 ml of Tryptic Soy Broth (BD Biosciences). Bacteria were then 
washed and resuspended in PBS prior to infection. CpG-B (1826) was from 
Coley Pharmaceutical Group (Wellesley, MA). poly IC was purchased from 
Amersham (Piscataway, NJ). LPS was purchased from Sigma-Aldrich (St. Louis, 
MI) and re-purified with Phenol. Pam2CSK4 was purchased from InvivoGen (San 
Diego, CA). 
Luciferase reporter assays and Western-Blotting  
Luciferase reporter assays were conducted as previously described (95). 
Briefly, 293T cells (2.104 cells/well in 96-well plates) were transfected with 40ng 
luciferase reporter genes together with 40ng pGL4-TK Renilla-luciferase reporter 
gene and with the indicated expression plasmids using Genejuice (Novagen, 
Madison, WI). Luciferase activity was measured as previously described (210). 
Whole cell lysate left from reporter assay were analyzed by 10% SDS-PAGE and 
subjected to immunoblot analysis using anti-Flag antibody (Sigma-Aldrich, St. 
Louis, MI).  
In vitro kinase assay 
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The kinase assay was performed as previously described (251). Briefly, 
the reaction was prepared in 10µl of buffer A (20mM Hepes, pH7.6/20mM β -
glycerophosphate/0.1mM sodium orthovanadate/10mM MgCl2/50mM NaCl/1mM 
DTT) containing 1µg of IRF5 or MBP (Upstate, Lake placid, NY) protein substrate 
and 10ng recombinant TBK1 protein (from Dr. McWhirter, UC Berkeley, CA) or 
RIP2 protein (Upstate, Lake placid, NY), 50µM ATP, and 5µCi of [γ-32P]ATP (1Ci 
= 37GBq), and conducted at 30°C for 30 min. Reaction products were subjected 
to analysis in 10% SDS- PAGE gels.  
Real time quantitative PCR analysis 
Total RNA was extracted from the macrophage or splenic DCs 
(2.106cells/w in 6w plates) stimulated with TLR ligands or viruses using RNeasy 
(Qiagen, Valencia CA) or from macrophages (1.106cells/w in 6w plates) infected 
with bacteria or N-Glycolyl-MDP using Trizol reagent (Invitrogen) according to the 
manufacturer's directions. cDNA were synthesized as previously described 
(HMPV paper ref 29) using the SuperScript III enzyme (Invitrogen). Quantitative 
real-time PCR was performed using SYBR green reagent (Bio-Rad, Hercules 
CA) with the following primers: mIFNβ-F, 5′-CGTCTCCTGGATGAACTCCAC; 
mIFNβ-R, TGAGGACATCTCCCACGTCA; β -actin-F, 5′-
CGAGGCCCAGAGCAAGAGAG; β -actin-R, 5′-CGGTTGGCCTTAGGGTTCAG; 
mTNFα-F, CAGTTCTATGGCCCAGACCCT; mTNFα-R, 
CGGACTCCGCAAAGTCTAAG; Results shown are representative of more than 
three separate infection experiments, with each PCR performed in triplicate. All 
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values reported were in the linear range of the experiment and were normalized 
to β-actin values.  
Bone Marrow-derived Macrophages, DCs, Splenic DC Preparations 
Bone marrow was flushed out of the femurs and differentiated into 
macrophages for 10 days in DMEM (Mediatech Inc, Herndon VA) supplemented 
with 20% L929-cell conditioned medium (which produce macrophage colony-
stimulating factor), 10% fetal bovine serum (Hyclone, Logan UT), and 10mg/ml 
Ciprofloxacin (Mediatech Inc). Bone marrow was differentiated into DCs for 10 
days in RPMI (Mediatech Inc, Herndon VA) supplemented with 20ng/ml of GM-
CSF (PeproTech, Rocky Hill, NJ), 10% fetal bovine serum (Hyclone, Logan UT), 
and 10mg/ml Ciprofloxacin (Mediatech Inc). Splenic CD11c+CDC or panDC was 
isolated by positive selection using CD11c+ or panDC MACS beads (Miltenyi 
Biotec).  
ELISA 
For ELISA analysis, BMDMs or splenic DCs (2.105/well) were plated in 96 
well plates in 200ul and stimulated for 24h. mTNFα was measured according to 
the manufacturer’s recommendations (eBioscience, San Diego, CA). A murine 
IFNβ sandwich ELISA was used as previously described (212).  
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Chapter V Discussion and Perspectives 
5.1 Cell type specific response 
Protective innate immune responses begin when PRRs recognize 
microbial ligands. What has emerged from studies over the last 10-15 years or so 
is that multiple classes of PRRs recognize microbial components in cell type-
specific manners due to the differential expression of receptors in different 
immune cell types. In chapter II of this thesis, we revealed that the recognition of 
two closely related viruses, HMPV strains (A1 [NL\1\00] and B1 [NL\1\99]) 
triggered different classes of PRRs depending on the cell types tested. We 
began our studies of PRR sensing of viruses with human cell lines. Initially, we 
focused on HEK293 cells given their wide use in the field of innate immune 
study. These cell lines have been proven to be very useful model cells to study 
cytosolic nucleic acid sensing pathways. In fact, RIG-I and most cytosolic DNA 
sensors have been discovered in HEK293 cells. In addition to the use of 
HEK293, we also used A549 cells, which are a human airway epithelial cell line 
commonly used to study immune responses to respiratory pathogens such as 
HMPV. Although cell lines feature most of the characteristics of primary cells and 
have the advantage of being able to be expanded in large numbers for 
biochemical assays and are easily transfectable, they often do not fully represent 
what is seen in primary cells or in vivo. For these reasons we extended our 
studies in cell lines to these human viruses in more relevant human primary cells 
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isolated from human PBMCs. A comprehensive analysis of cell line responses, 
combined with primary cell analysis is therefore a better approach.  
Our studies in cell lines and primary cells allowed us to reveal, that in most 
cell types tested including human cell lines and purified human monocytes, 
HMPVA1 was sensed by the cytosolic RNA receptor RIG-I, in which 5’- 
triphosphate RNA is the viral ligand triggering the response. The exception to this 
was what we found in PDCs, where both A1 and B1 strains were sensed more or 
less equivalently to turn on type I IFN responses through a TLR7 dependent 
mechanism. One explanation for this differential sensing in these cells is that 
TLR7 expression is restricted to B cells and PDCs (at least in humans) while 
RIG-I appears to be expressed more broadly. PDCs do not appear to express 
RIG-I although its expression can be inducible by IFN production. The delayed 
expression of RIG-I might not cause significant differences in the induction of 
type I IFN by A1 or B1 viruses since the early robust expression of IFNα in PDC 
via TLR7 amplifies type I IFN production through IFNR signalling. It is possible 
however, that after prolonged IFN treatment, RIG-I expression may be turned on 
and RIG-I could play a role to cooperate with TLRs for later IFN production in 
these cells. TLR7 is expressed in the endosomal compartment where it samples 
viral genomes to turn on signalling. The acidic compartment of endosomes 
unveils the viral RNA for detection in this case. HMPV viruses are 
paramyxoviruses, which replicate in the cytosol. The lack of RIG-I in these cells 
means there is no apparent cytosolic detection of this virus. Endosomal sensing 
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is thus employed. One possibility for these observations is that viruses enter cells 
via the endocytic pathway in PDCs in contrast to other cell types. Another 
possibility is that cytosolic viral nucleic acids are delivered to the endosome to 
TLRs for sensing. Indeed, we have preliminary evidence that suggested a role for 
autophagy in PDC sensing of HMPV, since 3-MA and wortmannin, which inhibit 
the autophagy machinery block IFN responses in PDCs.  Actually, tracking the 
viral entry pathways, for example using fluorescently labelled viruses/viral 
genomes, would be ideal to help explain the differential sensing in different cell 
types. We did attempt to perform such studies, but failed to clearly visualize virus 
trafficking patterns using the methods we used. Such cell type specific 
involvement of the RIG-I versus TLR pathways in induction of antiviral responses 
is not unique to HMPV viruses, as this differential sensing has previously been 
reported in the case of sensing of NDV (151). In vivo, it is likely that both PDCs 
and other DC subtypes, as well as macrophages, epithelial cells etc. could 
contribute to the overall anti-viral response. Indeed in the case of DNA viruses, 
Rasmussen et. al. also showed that in response to HSV, early production of IFN 
in vivo is mediated through TLR9 in PDCs, while the subsequent type I IFN 
response comes from several cell types and  independent of TLR9. This report is 
consistent with the idea that the antiviral response is regulated in a cell type 
specific and temporal manner with different cell types and PRRs contributing at 
different stages of the infection in vivo.  
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The ability of different cell types to turn on IFN is not only due to the 
different receptors involved but is also related to the downstream pathways and 
signaling mediators expressed in those cells. The three major adaptor proteins of 
TLRs and RLRs, MyD88, TRIF, and MAVS, recruit different combinations of 
effectors, such as kinases and IRFs depending on the cell types. For example, in 
most cell types, IRF3 plays the predominant role in IFN induction pathways, 
however the high level expression of IRF7 in PDCs dictates the preferential 
induction of IFNα rather than IFNβ in these cells. As suggested by our studies on 
IRF5, detailed in chapter IV, depending on the cell type, different IRFs may be 
employed to participate in the IFN response.  In the context of the whole animal 
however, when one monitors total IFN production in vivo, this response is a sum 
of the IFN levels coming from all the different cell types and therefore it might be 
difficult to clearly reveal the importance of a specific IRF. In this sense, in vitro 
assays with individual cell types would be more relevant than in vivo models of 
whole animals to clarify the specific role of each mediator. 
Innate antiviral immune responses in vivo involve different subsets of DCs, 
as well as macrophages, natural killer cells and non-hematopoietic cells. It is 
important that immune responses to viruses involve tightly controlled and 
temporally regulated responses. If all cells from different tissues, and locations 
responded in exactly the same manner at the same time to viral infection, there 
could be overproduction of interferon and cytokines which could have a 
damaging effect on the host. For example, overproduction of type I IFNs is 
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associated with SLE. The cell type specific and temporal manner in which cells 
regulate IFNs and other cytokines allows effective host-defense while at the 
same time preventing excessive production of these mediators.  
The ability of different cell types to induce the same responses, through 
different sensors and signalling pathways also adds redundancy to the defence 
system. Viruses are experts at evading innate defenses, particularly those that 
turn on IFN. The studies outlined in Chapter III provide a good example of this 
phenomenon and emphasizes the importance of functional redundancy for the 
fight between host and invader. Our studies revealed that HMPVB1 strains can 
prevent the RIG-I pathway from being activated in most cell types. However, the 
B1 virus is detected normally in PDCs and sensing of B1 in PDCs is not sensitive 
to B1 P protein mediated antagonism, because in this cell, B1 is not sensed by 
RIG-I but rather by the TLR system. Thus, HMPV viruses trigger two pathways to 
generate IFN. The involvement of two pathways means that even when one arm 
of the response is disabled, a second pathway is still functional to allow an 
effective immune response. This may be particularly relevant in vivo where the 
PDC are thought to be responsible for most of the IFN produced in the 
circulation. Even if the virus thwarts sensing by cells at the site of infection, the 
ability of PDCs to respond normally could still have a significant impact on control 
of this virus in vivo.  
Functional redundancy also appears to be important in DNA sensing and 
in TLR4 signaling. A number of DNA sensing pathways have been identified 
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including DAI and RNA polymerase III which likely work in redundant manners. 
Similarly, TLR4 uses four adapter molecules, MyD88, Mal/TIRAP, TRIF and 
TRAM to coordinate downstream signaling. NFκB can be activated by two 
different mechanisms in this case. The Mal/MyD88 pathway leads to NFκB 
activation via IRAK kinases while the TRIF/TRAM arm of this pathway leads to 
NFκB via RIP1 kinases. One can imagine how pathogens might disarm one of 
these pathways, but the redundancy built into the system allows the host to still 
elicit the protective responses required to eliminate the pathogen.  
Cell type specific expression of different receptors or responsiveness to a 
given agent can have practical implications. For example, distinct subtypes of 
breast tumors that arise from different cell types and these tumors show 
significant differences in responses to chemotherapeutic agents (252). Drug 
delivery by targeting drugs to bind to receptors and accumulate inside specific 
cells is an example of how such an approach could be useful therapeutically. 
Thus, drugs can act locally in specific tissues or organs, which can increase their 
efficacy and reduce harmful side effects which might occur if the drug acted 
systemically.  
 
5.2 Viral antagonism 
When potent cytokines especially type I IFNs are quickly produced upon 
viral infection, viral replication will be restricted. It is clear that viruses have 
evolved all kinds of strategies to block their recognition by the immune system 
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and fight against the production of antiviral effectors, so that they can proliferate 
and spread in the host. Our studies comparing the HMPVA1 and B1 strains led 
us to identify a novel immune evasion mechanism. We found that the B1 strain 
failed to induce innate signaling in most cell types and our studies with individual 
B1 proteins and recombinant viruses in which we swapped P proteins from the 
B1 virus with those from the A1 virus, allowed us to propose a mechanism 
whereby in the context of the entire virus, the P protein from the B1 virus is the 
likely factor that prevents RIG-I from sensing HMPV B1 virus. This conclusion 
was based on the following observations: 1. that the P protein from the B1 strain 
could prevent HMPVA1 virus from being recognized, 2. that under conditions 
when free viral RNA was delivered to the cytosol, the RNA from both A1 and B1 
strains could be recognized and turn on RIG-I signaling, 3. that the B1 P protein 
did not block RIG-I from recognizing NDV, a virus which is sensed by RIG-I and 
finally, 4). That recombinant A1 virus with the P protein from B1 failed to induce 
type I IFN production. These combined data suggested to us that in the context 
of the virus, the B1 P protein was preventing access of RIG-I to the viral RNA. 
This explanation is particularly strengthened by the fact that free viral RNA is 
sensed normally. Moreover, the factor that the B1 P protein allows normal 
sensing of NDV RNA indicates that the block is at the level of HMPV RNA 
access/sensing. Our failure to recover recombinant B1 virus encoding P protein 
from the A1 strain prevented us from testing the possibility that this was the only 
contributing factor. If in the B1 backbone, the P protein from the A1 virus did not 
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block A1 virus from being sensed, this would have strengthened this argument. 
We therefore cannot exclude the possibility that other proteins (from the B1 
strain) also contribute to this antagonism.  
Previously published data has suggested that the G protein could also 
have an inhibitory effect on the Rig-I pathway (224). These studies however, 
utilized a different strain of HMPV virus, CAN97-83 strain. In our own studies with 
A1 and B1 strains, we failed to see any effects of the G protein from the B1 virus 
on RIG-I sensing. Generating chimeric viruses in the A1 and B1 strains in which 
the G protein was deleted or exchanged would allow us to clarify this issue. In 
light of our current data, we propose a model in which the P protein inhibits type I 
IFN induction through RIG-I by preventing RIG-I from detecting the viral DNA. 
Importantly, our studies in PDC reveal that the P protein does not prevent TLR7 
mediated recognition, since both A1 and B1 viruses are sensed normally via 
TLR7 in the endosomal. Of note, TLR7 senses ssRNA and a 5’ tri-phosphate 
group is not required for this sensing. Specifically, the B1 P protein masks the 
RIG-I ligand in the cytosol.    
A detailed comparison of in vivo responses in mice to HMPVA1 and B1 
viruses could be used to further examine the differential innate sensing of these 
viruses and the impact of the B1 P protein on viral pathogenesis. Based on our 
findings in this thesis in vitro, we would speculate that the failure of the RIG-I 
pathway to induce IFN in response to the B1 virus might make this strain more 
virulent allowing greater viral replication. However, the fact that PDC can trigger 
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IFN in response to B1 could be sufficient to control viral levels in vivo. We don’t 
yet have clinical data comparing the effect of these two human viruses in human 
populations, which would be more relevant than mouse models. One recent 
study from Vicente & al. described how acute respiratory illness (ARI) due to 
HMPV-A strains was more severe than that due to HMPV-B viruses (253). One 
possible interpretation of this finding based on our studies might relate to the fact 
that the RIG-I pathway also regulates inflammatory cytokines as well as IFN. It is 
possible that the ability of A viruses but not B1 virus to trigger RIG-I could 
account for a more aggressive inflammatory response to A1 versus B1 virus. By 
understanding how viruses trigger and evade innate sensors, one can develop 
deletion mutants, which are attenuated in vivo that could be developed as 
vaccine candidates. 
5.3 Summary 
In this thesis, we have studied the innate immune response to RNA 
viruses and ligands for TLR7 and 9. A clear understanding of how viruses are 
detected and how viruses subvert these recognition systems and overcome 
innate defenses is critical for our ability to treat viral pathogenesis and develop 
new vaccines for viruses.  
While most of the work in this thesis focused on RNA sensing of viruses, it 
is becoming more and more clear that a variety of bacterial pathogens also 
trigger type I IFN response. It is likely that IFN response to bacteria will also 
involve other receptor families besides the major viral detecting TLRs and RLRs. 
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In the second part of chapter IV our data showed that stimulation with MDP 
isolated from Mtb can activate NOD2-RIP2-IRF5 signaling pathway and is 
sufficient to induce type I IFN production. While in response to whole Mtb, both 
IRF3 and IRF5 are required for full activation of type I IFN, again indicating  that 
redundant pathways exist for sensing Mtb infection. The redundancy employed 
here could also be important in situations where bacterial evasion of one or more 
of these immune responses comes into play.  
Understanding how the activity of IRFs as well as other signaling 
mediators is regulated can help to understand how disease related versions of 
these molecules can contribute to disease pathogenesis. For example, some 
mutations in IRF5 are associated with the pathogenesis of autoimmune disease 
including inflammatory bowel disease (IBD), systemic lupus erythematosus 
(SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS) (228, 229, 254-256). 
Our understanding of IRF5 function in TLR and NLR signaling could be of 
potential importance for developing clinical therapies to treat these important 
diseases. 
In summary, in this thesis, by studying HMPV viruses and IRF5 signaling 
we have explored new aspects of innate immunity. Our findings help us to 
understand how important innate sensing can be and in particular reveal that 
innate sensing and signaling pathways need to be tightly controlled or else there 
are deleterious consequences for the host: in the case of virus infection, over 
activation of innate pathways can contribute to viral pathogenesis. While in the 
144
case of IRF5, as suggested by the disease associated SNPs, mutant versions 
could lead to excessive IFN responses and diseases like SLE. A deeper 
understanding of the molecular mechanisms involved in interactions between 
host and microbes will help to develop better preventive and therapeutic 
strategies against infectious and autoimmune diseases. 
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